{"id": "AIMed.d91.s776_AIMed.d91.s776.p0", "text": "Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.", "text_with_entity_marker": "Molecular cloning and expression of the 32-kDa subunit of human [E1]TFIID[/E1] reveals interactions with [E2]VP16[/E2] and TFIIB that mediate transcriptional activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[64, 69]], "entity_1_idx_in_text_with_entity_marker": [68, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s776_AIMed.d91.s776.p1", "text": "Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.", "text_with_entity_marker": "Molecular cloning and expression of the 32-kDa subunit of human [E1]TFIID[/E1] reveals interactions with VP16 and [E2]TFIIB[/E2] that mediate transcriptional activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[64, 69]], "entity_1_idx_in_text_with_entity_marker": [68, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s776_AIMed.d91.s776.p2", "text": "Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.", "text_with_entity_marker": "Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with [E1]VP16[/E1] and [E2]TFIIB[/E2] that mediate transcriptional activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VP16", "entity_1_idx": [[96, 100]], "entity_1_idx_in_text_with_entity_marker": [100, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s777_AIMed.d91.s777.p0", "text": "Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).", "text_with_entity_marker": "Transcription factor [E1]TFIID[/E1] consists of [E2]TATA binding protein[/E2] (TBP) and at least eight TBP-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA binding protein", "entity_2_idx": [[39, 59]], "entity_2_idx_in_text_with_entity_marker": [52, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s777_AIMed.d91.s777.p1", "text": "Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).", "text_with_entity_marker": "Transcription factor [E1]TFIID[/E1] consists of TATA binding protein ([E2]TBP[/E2]) and at least eight TBP-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s777_AIMed.d91.s777.p2", "text": "Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).", "text_with_entity_marker": "Transcription factor [E1]TFIID[/E1] consists of TATA binding protein (TBP) and at least eight [E2]TBP[/E2]-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[85, 88]], "entity_2_idx_in_text_with_entity_marker": [98, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s777_AIMed.d91.s777.p3", "text": "Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).", "text_with_entity_marker": "Transcription factor TFIID consists of [E1]TATA binding protein[/E1] ([E2]TBP[/E2]) and at least eight TBP-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[39, 59]], "entity_1_idx_in_text_with_entity_marker": [43, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s777_AIMed.d91.s777.p4", "text": "Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).", "text_with_entity_marker": "Transcription factor TFIID consists of [E1]TATA binding protein[/E1] (TBP) and at least eight [E2]TBP[/E2]-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[39, 59]], "entity_1_idx_in_text_with_entity_marker": [43, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[85, 88]], "entity_2_idx_in_text_with_entity_marker": [98, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s777_AIMed.d91.s777.p5", "text": "Transcription factor TFIID consists of TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs).", "text_with_entity_marker": "Transcription factor TFIID consists of TATA binding protein ([E1]TBP[/E1]) and at least eight [E2]TBP[/E2]-associated factors (TAFs).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[85, 88]], "entity_2_idx_in_text_with_entity_marker": [98, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s779_AIMed.d91.s779.p0", "text": "Here we report the cloning, expression, and biochemical characterization of the 32-kDa subunit of human (h) TFIID, termed hTAFII32.", "text_with_entity_marker": "Here we report the cloning, expression, and biochemical characterization of the 32-kDa subunit of human (h) [E1]TFIID[/E1], termed [E2]hTAFII32[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAFII32", "entity_2_idx": [[122, 130]], "entity_2_idx_in_text_with_entity_marker": [135, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s780_AIMed.d91.s780.p0", "text": "We find that hTAFII32 is the human homologue of Drosophila TAFII40.", "text_with_entity_marker": "We find that [E1]hTAFII32[/E1] is the human homologue of Drosophila [E2]TAFII40[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAFII32", "entity_1_idx": [[13, 21]], "entity_1_idx_in_text_with_entity_marker": [17, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[59, 66]], "entity_2_idx_in_text_with_entity_marker": [72, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p0", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila [E1]TAFII40[/E1], [E2]hTAFII32[/E2] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[84, 91]], "entity_1_idx_in_text_with_entity_marker": [88, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAFII32", "entity_2_idx": [[93, 101]], "entity_2_idx_in_text_with_entity_marker": [106, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p1", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila [E1]TAFII40[/E1], hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator [E2]viral protein 16[/E2] (VP16) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[84, 91]], "entity_1_idx_in_text_with_entity_marker": [88, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "viral protein 16", "entity_2_idx": [[193, 209]], "entity_2_idx_in_text_with_entity_marker": [206, 222], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p2", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila [E1]TAFII40[/E1], hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 ([E2]VP16[/E2]) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[84, 91]], "entity_1_idx_in_text_with_entity_marker": [88, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p3", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila [E1]TAFII40[/E1], hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[84, 91]], "entity_1_idx_in_text_with_entity_marker": [88, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[266, 271]], "entity_2_idx_in_text_with_entity_marker": [279, 284], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p4", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, [E1]hTAFII32[/E1] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator [E2]viral protein 16[/E2] (VP16) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hTAFII32", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "viral protein 16", "entity_2_idx": [[193, 209]], "entity_2_idx_in_text_with_entity_marker": [206, 222], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p5", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, [E1]hTAFII32[/E1] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 ([E2]VP16[/E2]) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hTAFII32", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p6", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, [E1]hTAFII32[/E1] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor [E2]TFIIB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hTAFII32", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[266, 271]], "entity_2_idx_in_text_with_entity_marker": [279, 284], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p7", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator [E1]viral protein 16[/E1] ([E2]VP16[/E2]) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "viral protein 16", "entity_1_idx": [[193, 209]], "entity_1_idx_in_text_with_entity_marker": [197, 213], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p8", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator [E1]viral protein 16[/E1] (VP16) as well as with the general transcription factor [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "viral protein 16", "entity_1_idx": [[193, 209]], "entity_1_idx_in_text_with_entity_marker": [197, 213], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[266, 271]], "entity_2_idx_in_text_with_entity_marker": [279, 284], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p9", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 ([E1]VP16[/E1]) as well as with the general transcription factor [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VP16", "entity_1_idx": [[211, 215]], "entity_1_idx_in_text_with_entity_marker": [215, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[266, 271]], "entity_2_idx_in_text_with_entity_marker": [279, 284], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s782_AIMed.d91.s782.p0", "text": "Moreover, a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain.", "text_with_entity_marker": "Moreover, a partial recombinant [E1]TFIID[/E1] complex containing [E2]hTAFII32[/E2] was capable of mediating in vitro transcriptional activation by the VP16 activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAFII32", "entity_2_idx": [[57, 65]], "entity_2_idx_in_text_with_entity_marker": [70, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s782_AIMed.d91.s782.p1", "text": "Moreover, a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain.", "text_with_entity_marker": "Moreover, a partial recombinant [E1]TFIID[/E1] complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the [E2]VP16[/E2] activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s782_AIMed.d91.s782.p2", "text": "Moreover, a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain.", "text_with_entity_marker": "Moreover, a partial recombinant TFIID complex containing [E1]hTAFII32[/E1] was capable of mediating in vitro transcriptional activation by the [E2]VP16[/E2] activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAFII32", "entity_1_idx": [[57, 65]], "entity_1_idx_in_text_with_entity_marker": [61, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d9.s73_AIMed.d9.s73.p0", "text": "We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor (CaR).", "text_with_entity_marker": "We investigated the mechanism of calcium-stimulated [E1]gastrin[/E1] release from gastrinoma cells in vitro with a particular focus on the [E2]calcium-sensing receptor[/E2] (CaR).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gastrin", "entity_1_idx": [[52, 59]], "entity_1_idx_in_text_with_entity_marker": [56, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calcium-sensing receptor", "entity_2_idx": [[130, 154]], "entity_2_idx_in_text_with_entity_marker": [143, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d9.s73_AIMed.d9.s73.p1", "text": "We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor (CaR).", "text_with_entity_marker": "We investigated the mechanism of calcium-stimulated [E1]gastrin[/E1] release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor ([E2]CaR[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gastrin", "entity_1_idx": [[52, 59]], "entity_1_idx_in_text_with_entity_marker": [56, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaR", "entity_2_idx": [[156, 159]], "entity_2_idx_in_text_with_entity_marker": [169, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d9.s73_AIMed.d9.s73.p2", "text": "We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium-sensing receptor (CaR).", "text_with_entity_marker": "We investigated the mechanism of calcium-stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the [E1]calcium-sensing receptor[/E1] ([E2]CaR[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calcium-sensing receptor", "entity_1_idx": [[130, 154]], "entity_1_idx_in_text_with_entity_marker": [134, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaR", "entity_2_idx": [[156, 159]], "entity_2_idx_in_text_with_entity_marker": [169, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d9.s80_AIMed.d9.s80.p0", "text": "Our results demonstrated that CaR was expressed in human gastrinoma cells and could be involved in the mechanism of calcium-evoked gastrin release.", "text_with_entity_marker": "Our results demonstrated that [E1]CaR[/E1] was expressed in human gastrinoma cells and could be involved in the mechanism of calcium-evoked [E2]gastrin[/E2] release.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CaR", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gastrin", "entity_2_idx": [[131, 138]], "entity_2_idx_in_text_with_entity_marker": [144, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1660_AIMed.d195.s1660.p0", "text": "Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.", "text_with_entity_marker": "Competitive binding of [E1]alpha-actinin[/E1] and [E2]calmodulin[/E2] to the NMDA receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-actinin", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [27, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[41, 51]], "entity_2_idx_in_text_with_entity_marker": [54, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1660_AIMed.d195.s1660.p1", "text": "Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.", "text_with_entity_marker": "Competitive binding of [E1]alpha-actinin[/E1] and calmodulin to the [E2]NMDA receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "alpha-actinin", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [27, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[59, 72]], "entity_2_idx_in_text_with_entity_marker": [72, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1660_AIMed.d195.s1660.p2", "text": "Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.", "text_with_entity_marker": "Competitive binding of alpha-actinin and [E1]calmodulin[/E1] to the [E2]NMDA receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "calmodulin", "entity_1_idx": [[41, 51]], "entity_1_idx_in_text_with_entity_marker": [45, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[59, 72]], "entity_2_idx_in_text_with_entity_marker": [72, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p0", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E2]alpha-Actinin-2[/E2], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-Actinin-2", "entity_2_idx": [[221, 236]], "entity_2_idx_in_text_with_entity_marker": [234, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p1", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E2]dystrophin[/E2] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[263, 273]], "entity_2_idx_in_text_with_entity_marker": [276, 286], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p2", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E2]actin[/E2]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p3", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E2]PSD-95[/E2]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[475, 481]], "entity_2_idx_in_text_with_entity_marker": [488, 494], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p4", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E2]alpha-Actinin-2[/E2] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-Actinin-2", "entity_2_idx": [[483, 498]], "entity_2_idx_in_text_with_entity_marker": [496, 511], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p5", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E2]NR1[/E2] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR1", "entity_2_idx": [[563, 566]], "entity_2_idx_in_text_with_entity_marker": [576, 579], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p6", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p7", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p8", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of [E1]actin[/E1], suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p9", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/[E2]dystrophin[/E2] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[263, 273]], "entity_2_idx_in_text_with_entity_marker": [276, 286], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p10", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of [E2]actin[/E2]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p11", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E2]PSD-95[/E2]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[475, 481]], "entity_2_idx_in_text_with_entity_marker": [488, 494], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p12", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E2]alpha-Actinin-2[/E2] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-Actinin-2", "entity_2_idx": [[483, 498]], "entity_2_idx_in_text_with_entity_marker": [496, 511], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p13", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E2]NR1[/E2] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR1", "entity_2_idx": [[563, 566]], "entity_2_idx_in_text_with_entity_marker": [576, 579], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p14", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p15", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p16", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. [E1]alpha-Actinin-2[/E1], a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[221, 236]], "entity_1_idx_in_text_with_entity_marker": [225, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p17", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of [E2]actin[/E2]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[284, 289]], "entity_2_idx_in_text_with_entity_marker": [297, 302], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p18", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E2]PSD-95[/E2]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[475, 481]], "entity_2_idx_in_text_with_entity_marker": [488, 494], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p19", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E2]alpha-Actinin-2[/E2] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-Actinin-2", "entity_2_idx": [[483, 498]], "entity_2_idx_in_text_with_entity_marker": [496, 511], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p20", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E2]NR1[/E2] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR1", "entity_2_idx": [[563, 566]], "entity_2_idx_in_text_with_entity_marker": [576, 579], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p21", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p22", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p23", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/[E1]dystrophin[/E1] family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[263, 273]], "entity_1_idx_in_text_with_entity_marker": [267, 277], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p24", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E1]actin[/E1]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E2]PSD-95[/E2]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [288, 293], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[475, 481]], "entity_2_idx_in_text_with_entity_marker": [488, 494], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p25", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E1]actin[/E1]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E2]alpha-Actinin-2[/E2] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [288, 293], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-Actinin-2", "entity_2_idx": [[483, 498]], "entity_2_idx_in_text_with_entity_marker": [496, 511], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p26", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E1]actin[/E1]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E2]NR1[/E2] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [288, 293], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR1", "entity_2_idx": [[563, 566]], "entity_2_idx_in_text_with_entity_marker": [576, 579], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p27", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E1]actin[/E1]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [288, 293], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p28", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E1]actin[/E1]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [288, 293], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p29", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of [E1]actin[/E1]-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[284, 289]], "entity_1_idx_in_text_with_entity_marker": [288, 293], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p30", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E1]PSD-95[/E1]. [E2]alpha-Actinin-2[/E2] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PSD-95", "entity_1_idx": [[475, 481]], "entity_1_idx_in_text_with_entity_marker": [479, 485], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-Actinin-2", "entity_2_idx": [[483, 498]], "entity_2_idx_in_text_with_entity_marker": [496, 511], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p31", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E1]PSD-95[/E1]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E2]NR1[/E2] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PSD-95", "entity_1_idx": [[475, 481]], "entity_1_idx_in_text_with_entity_marker": [479, 485], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR1", "entity_2_idx": [[563, 566]], "entity_2_idx_in_text_with_entity_marker": [576, 579], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p32", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E1]PSD-95[/E1]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PSD-95", "entity_1_idx": [[475, 481]], "entity_1_idx_in_text_with_entity_marker": [479, 485], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p33", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E1]PSD-95[/E1]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PSD-95", "entity_1_idx": [[475, 481]], "entity_1_idx_in_text_with_entity_marker": [479, 485], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p34", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule [E1]PSD-95[/E1]. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PSD-95", "entity_1_idx": [[475, 481]], "entity_1_idx_in_text_with_entity_marker": [479, 485], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p35", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E1]alpha-Actinin-2[/E1] binds by its central rod domain to the cytoplasmic tail of both [E2]NR1[/E2] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[483, 498]], "entity_1_idx_in_text_with_entity_marker": [487, 502], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR1", "entity_2_idx": [[563, 566]], "entity_2_idx_in_text_with_entity_marker": [576, 579], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p36", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E1]alpha-Actinin-2[/E1] binds by its central rod domain to the cytoplasmic tail of both NR1 and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[483, 498]], "entity_1_idx_in_text_with_entity_marker": [487, 502], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p37", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E1]alpha-Actinin-2[/E1] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[483, 498]], "entity_1_idx_in_text_with_entity_marker": [487, 502], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p38", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E1]alpha-Actinin-2[/E1] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[483, 498]], "entity_1_idx_in_text_with_entity_marker": [487, 502], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p39", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E1]NR1[/E1] and [E2]NR2B[/E2] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR1", "entity_1_idx": [[563, 566]], "entity_1_idx_in_text_with_entity_marker": [567, 570], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NR2B", "entity_2_idx": [[571, 575]], "entity_2_idx_in_text_with_entity_marker": [584, 588], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p40", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E1]NR1[/E1] and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR1", "entity_1_idx": [[563, 566]], "entity_1_idx_in_text_with_entity_marker": [567, 570], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p41", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both [E1]NR1[/E1] and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR1", "entity_1_idx": [[563, 566]], "entity_1_idx_in_text_with_entity_marker": [567, 570], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p42", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E1]NR2B[/E1] subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR2B", "entity_1_idx": [[571, 575]], "entity_1_idx_in_text_with_entity_marker": [575, 579], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p43", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and [E1]NR2B[/E1] subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR2B", "entity_1_idx": [[571, 575]], "entity_1_idx_in_text_with_entity_marker": [575, 579], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p44", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E1]NMDA receptor[/E1], and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NMDA receptor", "entity_1_idx": [[592, 605]], "entity_1_idx_in_text_with_entity_marker": [596, 609], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1663_AIMed.d195.s1663.p0", "text": "Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin.", "text_with_entity_marker": "Intriguingly, [E1]NR1[/E1]-[E2]alpha-actinin[/E2] binding is directly antagonized by Ca2+/calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR1", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-actinin", "entity_2_idx": [[18, 31]], "entity_2_idx_in_text_with_entity_marker": [31, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1663_AIMed.d195.s1663.p1", "text": "Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin.", "text_with_entity_marker": "Intriguingly, [E1]NR1[/E1]-alpha-actinin binding is directly antagonized by Ca2+/[E2]calmodulin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NR1", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1663_AIMed.d195.s1663.p2", "text": "Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin.", "text_with_entity_marker": "Intriguingly, NR1-[E1]alpha-actinin[/E1] binding is directly antagonized by Ca2+/[E2]calmodulin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-actinin", "entity_1_idx": [[18, 31]], "entity_1_idx_in_text_with_entity_marker": [22, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s411_AIMed.d47.s411.p0", "text": "Crystal structure of the BMP-2-BRIA ectodomain complex.", "text_with_entity_marker": "Crystal structure of the [E1]BMP-2[/E1]-[E2]BRIA[/E2] ectodomain complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BRIA", "entity_2_idx": [[31, 35]], "entity_2_idx_in_text_with_entity_marker": [44, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s412_AIMed.d47.s412.p0", "text": "Bone morphogenetic proteins (BMPs) belong to the large transforming growth factor-beta (TGF-beta) superfamily of multifunctional cytokines.", "text_with_entity_marker": "Bone morphogenetic proteins (BMPs) belong to the large [E1]transforming growth factor-beta[/E1] ([E2]TGF-beta[/E2]) superfamily of multifunctional cytokines.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factor-beta", "entity_1_idx": [[55, 86]], "entity_1_idx_in_text_with_entity_marker": [59, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TGF-beta", "entity_2_idx": [[88, 96]], "entity_2_idx_in_text_with_entity_marker": [101, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s415_AIMed.d47.s415.p0", "text": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).", "text_with_entity_marker": "Here we report the crystal structure of human dimeric [E1]BMP-2[/E1] in complex with two high affinity [E2]BMP receptor IA[/E2] extracellular domains(BRIAec).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP receptor IA", "entity_2_idx": [[94, 109]], "entity_2_idx_in_text_with_entity_marker": [107, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s415_AIMed.d47.s415.p1", "text": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).", "text_with_entity_marker": "Here we report the crystal structure of human dimeric [E1]BMP-2[/E1] in complex with two high affinity [E2]BMP receptor IA extracellular domains[/E2](BRIAec).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP receptor IA extracellular domains", "entity_2_idx": [[94, 131]], "entity_2_idx_in_text_with_entity_marker": [107, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s415_AIMed.d47.s415.p2", "text": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).", "text_with_entity_marker": "Here we report the crystal structure of human dimeric [E1]BMP-2[/E1] in complex with two high affinity BMP receptor IA extracellular domains([E2]BRIAec[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BRIAec", "entity_2_idx": [[132, 138]], "entity_2_idx_in_text_with_entity_marker": [145, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s415_AIMed.d47.s415.p3", "text": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).", "text_with_entity_marker": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity [E1-E2]BMP receptor IA[/E1] extracellular domains[/E2](BRIAec).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP receptor IA", "entity_1_idx": [[94, 109]], "entity_1_idx_in_text_with_entity_marker": [101, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP receptor IA[/E1] extracellular domains", "entity_2_idx": [[94, 131]], "entity_2_idx_in_text_with_entity_marker": [101, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s415_AIMed.d47.s415.p4", "text": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).", "text_with_entity_marker": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity [E1]BMP receptor IA[/E1] extracellular domains([E2]BRIAec[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP receptor IA", "entity_1_idx": [[94, 109]], "entity_1_idx_in_text_with_entity_marker": [98, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BRIAec", "entity_2_idx": [[132, 138]], "entity_2_idx_in_text_with_entity_marker": [145, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s415_AIMed.d47.s415.p5", "text": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity BMP receptor IA extracellular domains(BRIAec).", "text_with_entity_marker": "Here we report the crystal structure of human dimeric BMP-2 in complex with two high affinity [E1]BMP receptor IA extracellular domains[/E1]([E2]BRIAec[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP receptor IA extracellular domains", "entity_1_idx": [[94, 131]], "entity_1_idx_in_text_with_entity_marker": [98, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BRIAec", "entity_2_idx": [[132, 138]], "entity_2_idx_in_text_with_entity_marker": [145, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d47.s416_AIMed.d47.s416.p0", "text": "The receptor chains bind to the 'wrist' epitopes of the BMP-2 dimer and contact both BMP-2 monomers.", "text_with_entity_marker": "The receptor chains bind to the 'wrist' epitopes of the [E1]BMP-2[/E1] dimer and contact both [E2]BMP-2[/E2] monomers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[56, 61]], "entity_1_idx_in_text_with_entity_marker": [60, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-2", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s379_AIMed.d44.s379.p0", "text": "Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.", "text_with_entity_marker": "Characterization of the [E1]CD30L[/E1] binding domain on the human [E2]CD30[/E2] molecule using anti-CD30 antibodies.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30L", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s379_AIMed.d44.s379.p1", "text": "Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.", "text_with_entity_marker": "Characterization of the [E1]CD30L[/E1] binding domain on the human CD30 molecule using anti-[E2]CD30[/E2] antibodies.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s379_AIMed.d44.s379.p2", "text": "Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.", "text_with_entity_marker": "Characterization of the CD30L binding domain on the human [E1]CD30[/E1] molecule using anti-[E2]CD30[/E2] antibodies.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[58, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p0", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "[E1]CD30[/E1] and its counter-receptor [E2]CD30[/E2] ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[30, 34]], "entity_2_idx_in_text_with_entity_marker": [43, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p1", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "[E1]CD30[/E1] and its counter-receptor [E2]CD30 ligand[/E2] (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30 ligand", "entity_2_idx": [[30, 41]], "entity_2_idx_in_text_with_entity_marker": [43, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p2", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "[E1]CD30[/E1] and its counter-receptor CD30 ligand ([E2]CD30L[/E2]) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p3", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "[E1]CD30[/E1] and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/[E2]TNFalpha[/E2] superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[82, 90]], "entity_2_idx_in_text_with_entity_marker": [95, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p4", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "CD30 and its counter-receptor [E1-E2]CD30[/E1] ligand[/E2] (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30[/E1] ligand", "entity_2_idx": [[30, 41]], "entity_2_idx_in_text_with_entity_marker": [37, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p5", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "CD30 and its counter-receptor [E1]CD30[/E1] ligand ([E2]CD30L[/E2]) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p6", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "CD30 and its counter-receptor [E1]CD30[/E1] ligand (CD30L) are members of the TNF-receptor/[E2]TNFalpha[/E2] superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[82, 90]], "entity_2_idx_in_text_with_entity_marker": [95, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p7", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "CD30 and its counter-receptor [E1]CD30 ligand[/E1] ([E2]CD30L[/E2]) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30 ligand", "entity_1_idx": [[30, 41]], "entity_1_idx_in_text_with_entity_marker": [34, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p8", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "CD30 and its counter-receptor [E1]CD30 ligand[/E1] (CD30L) are members of the TNF-receptor/[E2]TNFalpha[/E2] superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30 ligand", "entity_1_idx": [[30, 41]], "entity_1_idx_in_text_with_entity_marker": [34, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[82, 90]], "entity_2_idx_in_text_with_entity_marker": [95, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s380_AIMed.d44.s380.p9", "text": "CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation.", "text_with_entity_marker": "CD30 and its counter-receptor CD30 ligand ([E1]CD30L[/E1]) are members of the TNF-receptor/[E2]TNFalpha[/E2] superfamily and function to regulate lymphocyte survival and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[82, 90]], "entity_2_idx_in_text_with_entity_marker": [95, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p0", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble [E1]CD30L[/E1]/[E2]CD8alpha[/E2] chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD8alpha", "entity_2_idx": [[22, 30]], "entity_2_idx_in_text_with_entity_marker": [35, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p1", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble [E1]CD30L[/E1]/CD8alpha chimeric protein, we assessed the ability of anti-[E2]CD30[/E2] MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p2", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble [E1]CD30L[/E1]/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of [E2]CD30L[/E2] to CD30 expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p3", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble [E1]CD30L[/E1]/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to [E2]CD30[/E2] expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[125, 129]], "entity_2_idx_in_text_with_entity_marker": [138, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p4", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble CD30L/[E1]CD8alpha[/E1] chimeric protein, we assessed the ability of anti-[E2]CD30[/E2] MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD8alpha", "entity_1_idx": [[22, 30]], "entity_1_idx_in_text_with_entity_marker": [26, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p5", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble CD30L/[E1]CD8alpha[/E1] chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of [E2]CD30L[/E2] to CD30 expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD8alpha", "entity_1_idx": [[22, 30]], "entity_1_idx_in_text_with_entity_marker": [26, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p6", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble CD30L/[E1]CD8alpha[/E1] chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to [E2]CD30[/E2] expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD8alpha", "entity_1_idx": [[22, 30]], "entity_1_idx_in_text_with_entity_marker": [26, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[125, 129]], "entity_2_idx_in_text_with_entity_marker": [138, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p7", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-[E1]CD30[/E1] MAb to inhibit the binding of [E2]CD30L[/E2] to CD30 expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p8", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-[E1]CD30[/E1] MAb to inhibit the binding of CD30L to [E2]CD30[/E2] expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[125, 129]], "entity_2_idx_in_text_with_entity_marker": [138, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s383_AIMed.d44.s383.p9", "text": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line.", "text_with_entity_marker": "Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of [E1]CD30L[/E1] to [E2]CD30[/E2] expressed by the CD30+ Karpas 299 cell line.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30L", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[125, 129]], "entity_2_idx_in_text_with_entity_marker": [138, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s384_AIMed.d44.s384.p0", "text": "CD30L binding by CD30 is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44).", "text_with_entity_marker": "[E1]CD30L[/E1] binding by [E2]CD30[/E2] is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30L", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[17, 21]], "entity_2_idx_in_text_with_entity_marker": [30, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s385_AIMed.d44.s385.p0", "text": "Cluster Group B antibodies, including M67 and Ki-1, do not affect CD30L binding to CD30.", "text_with_entity_marker": "Cluster Group B antibodies, including M67 and Ki-1, do not affect [E1]CD30L[/E1] binding to [E2]CD30[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30L", "entity_1_idx": [[66, 71]], "entity_1_idx_in_text_with_entity_marker": [70, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s386_AIMed.d44.s386.p0", "text": "The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling.", "text_with_entity_marker": "The pattern of [E1]CD30L[/E1] binding inhibition shows only limited correspondence to the functional capacity of some anti-[E2]CD30[/E2] MAb to trigger CD30 signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s386_AIMed.d44.s386.p1", "text": "The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling.", "text_with_entity_marker": "The pattern of [E1]CD30L[/E1] binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger [E2]CD30[/E2] signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s386_AIMed.d44.s386.p2", "text": "The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling.", "text_with_entity_marker": "The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-[E1]CD30[/E1] MAb to trigger [E2]CD30[/E2] signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [118, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s387_AIMed.d44.s387.p0", "text": "Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction.", "text_with_entity_marker": "Finally, we demonstrate that the anti-[E1]CD30L[/E1] MAb M81 also completely inhibits [E2]CD30[/E2]/CD30L interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30", "entity_2_idx": [[77, 81]], "entity_2_idx_in_text_with_entity_marker": [90, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s387_AIMed.d44.s387.p1", "text": "Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction.", "text_with_entity_marker": "Finally, we demonstrate that the anti-[E1]CD30L[/E1] MAb M81 also completely inhibits CD30/[E2]CD30L[/E2] interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[82, 87]], "entity_2_idx_in_text_with_entity_marker": [95, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s387_AIMed.d44.s387.p2", "text": "Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction.", "text_with_entity_marker": "Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits [E1]CD30[/E1]/[E2]CD30L[/E2] interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD30", "entity_1_idx": [[77, 81]], "entity_1_idx_in_text_with_entity_marker": [81, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[82, 87]], "entity_2_idx_in_text_with_entity_marker": [95, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s388_AIMed.d44.s388.p0", "text": "This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.", "text_with_entity_marker": "This information is useful for applying these MAbs in functional studies to further investigate the [E1]CD30[/E1]/[E2]CD30L[/E2] system and for designing assays for soluble CD30L.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[100, 104]], "entity_1_idx_in_text_with_entity_marker": [104, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s388_AIMed.d44.s388.p1", "text": "This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.", "text_with_entity_marker": "This information is useful for applying these MAbs in functional studies to further investigate the [E1]CD30[/E1]/CD30L system and for designing assays for soluble [E2]CD30L[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30", "entity_1_idx": [[100, 104]], "entity_1_idx_in_text_with_entity_marker": [104, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[155, 160]], "entity_2_idx_in_text_with_entity_marker": [168, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d44.s388_AIMed.d44.s388.p2", "text": "This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.", "text_with_entity_marker": "This information is useful for applying these MAbs in functional studies to further investigate the CD30/[E1]CD30L[/E1] system and for designing assays for soluble [E2]CD30L[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD30L", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD30L", "entity_2_idx": [[155, 160]], "entity_2_idx_in_text_with_entity_marker": [168, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d35.s292_AIMed.d35.s292.p0", "text": "Most familial early-onset Alzheimer's disease cases are caused by mutations in the presenilin 1 (PS1) gene.", "text_with_entity_marker": "Most familial early-onset Alzheimer's disease cases are caused by mutations in the [E1]presenilin 1[/E1] ([E2]PS1[/E2]) gene.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "presenilin 1", "entity_1_idx": [[83, 95]], "entity_1_idx_in_text_with_entity_marker": [87, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[97, 100]], "entity_2_idx_in_text_with_entity_marker": [110, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d35.s294_AIMed.d35.s294.p0", "text": "Although numerous studies revealed predominant localization of PS1 to endoplasmic reticulum and Golgi, there are conflicting reports on the localization of PS1 to the cell surface.", "text_with_entity_marker": "Although numerous studies revealed predominant localization of [E1]PS1[/E1] to endoplasmic reticulum and Golgi, there are conflicting reports on the localization of [E2]PS1[/E2] to the cell surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[156, 159]], "entity_2_idx_in_text_with_entity_marker": [169, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d35.s299_AIMed.d35.s299.p0", "text": "Cell surface PS1 formed complexes in vivo with actin-binding protein filamin (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.", "text_with_entity_marker": "Cell surface [E1]PS1[/E1] formed complexes in vivo with actin-binding protein [E2]filamin[/E2] (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS1", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "filamin", "entity_2_idx": [[69, 76]], "entity_2_idx_in_text_with_entity_marker": [82, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d35.s299_AIMed.d35.s299.p1", "text": "Cell surface PS1 formed complexes in vivo with actin-binding protein filamin (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.", "text_with_entity_marker": "Cell surface [E1]PS1[/E1] formed complexes in vivo with actin-binding protein filamin ([E2]ABP-280[/E2]), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS1", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ABP-280", "entity_2_idx": [[78, 85]], "entity_2_idx_in_text_with_entity_marker": [91, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d35.s299_AIMed.d35.s299.p2", "text": "Cell surface PS1 formed complexes in vivo with actin-binding protein filamin (ABP-280), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.", "text_with_entity_marker": "Cell surface PS1 formed complexes in vivo with actin-binding protein [E1]filamin[/E1] ([E2]ABP-280[/E2]), which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "filamin", "entity_1_idx": [[69, 76]], "entity_1_idx_in_text_with_entity_marker": [73, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ABP-280", "entity_2_idx": [[78, 85]], "entity_2_idx_in_text_with_entity_marker": [91, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d34.s285_AIMed.d34.s285.p0", "text": "Presenilin 1 (PS1) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.", "text_with_entity_marker": "[E1]Presenilin 1[/E1] ([E2]PS1[/E2]) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Presenilin 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[14, 17]], "entity_2_idx_in_text_with_entity_marker": [27, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d34.s288_AIMed.d34.s288.p0", "text": "We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.", "text_with_entity_marker": "We report an interaction between the human [E1]PS1[/E1] or [E2]PS2[/E2] hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS2", "entity_2_idx": [[50, 53]], "entity_2_idx_in_text_with_entity_marker": [63, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d34.s288_AIMed.d34.s288.p1", "text": "We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.", "text_with_entity_marker": "We report an interaction between the human [E1]PS1[/E1] or PS2 hydrophilic loop and [E2]Rab11[/E2], a small GTPase belonging to the Ras-related superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS1", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rab11", "entity_2_idx": [[75, 80]], "entity_2_idx_in_text_with_entity_marker": [88, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d34.s288_AIMed.d34.s288.p2", "text": "We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.", "text_with_entity_marker": "We report an interaction between the human PS1 or [E1]PS2[/E1] hydrophilic loop and [E2]Rab11[/E2], a small GTPase belonging to the Ras-related superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS2", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rab11", "entity_2_idx": [[75, 80]], "entity_2_idx_in_text_with_entity_marker": [88, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d34.s289_AIMed.d34.s289.p0", "text": "Interaction domains were mapped to codons 374-400 for PS1 and to codons 106-179 for Rab11, a region including the fourth GTP-binding domain.", "text_with_entity_marker": "Interaction domains were mapped to codons 374-400 for [E1]PS1[/E1] and to codons 106-179 for [E2]Rab11[/E2], a region including the fourth GTP-binding domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PS1", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rab11", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d40.s347_AIMed.d40.s347.p0", "text": "We have crystallized a complex between human FGF1 and a two-domain extracellular fragment of human FGFR2.", "text_with_entity_marker": "We have crystallized a complex between human [E1]FGF1[/E1] and a two-domain extracellular fragment of human [E2]FGFR2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF1", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s562_AIMed.d66.s562.p0", "text": "Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.", "text_with_entity_marker": "Human [E1]cyclin E[/E1], a new cyclin that interacts with two members of the [E2]CDC2[/E2] gene family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[6, 14]], "entity_1_idx_in_text_with_entity_marker": [10, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC2", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s564_AIMed.d66.s564.p0", "text": "Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.", "text_with_entity_marker": "[E1]Cyclin E[/E1] showed genetic interactions with the [E2]CDC28[/E2] gene, suggesting that it functioned at START by interacting with the CDC28 protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cyclin E", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC28", "entity_2_idx": [[46, 51]], "entity_2_idx_in_text_with_entity_marker": [59, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s564_AIMed.d66.s564.p1", "text": "Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.", "text_with_entity_marker": "[E1]Cyclin E[/E1] showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the [E2]CDC28[/E2] protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cyclin E", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC28", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s564_AIMed.d66.s564.p2", "text": "Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.", "text_with_entity_marker": "Cyclin E showed genetic interactions with the [E1]CDC28[/E1] gene, suggesting that it functioned at START by interacting with the [E2]CDC28[/E2] protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC28", "entity_1_idx": [[46, 51]], "entity_1_idx_in_text_with_entity_marker": [50, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC28", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s565_AIMed.d66.s565.p0", "text": "Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation.", "text_with_entity_marker": "Two human genes were identified that could interact with [E1]cyclin E[/E1] to perform START in yeast containing a [E2]cdc28[/E2] mutation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin E", "entity_1_idx": [[57, 65]], "entity_1_idx_in_text_with_entity_marker": [61, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc28", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s566_AIMed.d66.s566.p0", "text": "One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.", "text_with_entity_marker": "One was [E1-E2]CDC2[/E1]-HS[/E2], and the second was the human homolog of Xenopus CDK2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC2", "entity_1_idx": [[8, 12]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC2[/E1]-HS", "entity_2_idx": [[8, 15]], "entity_2_idx_in_text_with_entity_marker": [15, 27], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s566_AIMed.d66.s566.p1", "text": "One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.", "text_with_entity_marker": "One was [E1]CDC2[/E1]-HS, and the second was the human homolog of Xenopus [E2]CDK2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC2", "entity_1_idx": [[8, 12]], "entity_1_idx_in_text_with_entity_marker": [12, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s566_AIMed.d66.s566.p2", "text": "One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.", "text_with_entity_marker": "One was [E1]CDC2-HS[/E1], and the second was the human homolog of Xenopus [E2]CDK2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC2-HS", "entity_1_idx": [[8, 15]], "entity_1_idx_in_text_with_entity_marker": [12, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s567_AIMed.d66.s567.p0", "text": "Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.", "text_with_entity_marker": "[E1]Cyclin E[/E1] produced in E. coli bound and activated the [E2]CDC2[/E2] protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cyclin E", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC2", "entity_2_idx": [[53, 57]], "entity_2_idx_in_text_with_entity_marker": [66, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s567_AIMed.d66.s567.p1", "text": "Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.", "text_with_entity_marker": "[E1]Cyclin E[/E1] produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against [E2]cyclin E[/E2] immunoprecipitated a histone H1 kinase from HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cyclin E", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[122, 130]], "entity_2_idx_in_text_with_entity_marker": [135, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s567_AIMed.d66.s567.p2", "text": "Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.", "text_with_entity_marker": "Cyclin E produced in E. coli bound and activated the [E1]CDC2[/E1] protein in extracts from human G1 cells, and antibodies against [E2]cyclin E[/E2] immunoprecipitated a histone H1 kinase from HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC2", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[122, 130]], "entity_2_idx_in_text_with_entity_marker": [135, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s568_AIMed.d66.s568.p0", "text": "The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.", "text_with_entity_marker": "The interactions between [E1]cyclin E[/E1] and [E2]CDC2[/E2], or CDK2, may be important at the G1 to S transition in human cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin E", "entity_1_idx": [[25, 33]], "entity_1_idx_in_text_with_entity_marker": [29, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDC2", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [51, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s568_AIMed.d66.s568.p1", "text": "The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.", "text_with_entity_marker": "The interactions between [E1]cyclin E[/E1] and CDC2, or [E2]CDK2[/E2], may be important at the G1 to S transition in human cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin E", "entity_1_idx": [[25, 33]], "entity_1_idx_in_text_with_entity_marker": [29, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d66.s568_AIMed.d66.s568.p2", "text": "The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.", "text_with_entity_marker": "The interactions between cyclin E and [E1]CDC2[/E1], or [E2]CDK2[/E2], may be important at the G1 to S transition in human cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CDC2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1635_AIMed.d192.s1635.p0", "text": "Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.", "text_with_entity_marker": "Activation of [E1-E2]interferon-gamma[/E1] inducing factor[/E2] mediated by interleukin-1beta converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[14, 30]], "entity_1_idx_in_text_with_entity_marker": [21, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon-gamma[/E1] inducing factor", "entity_2_idx": [[14, 46]], "entity_2_idx_in_text_with_entity_marker": [21, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1635_AIMed.d192.s1635.p1", "text": "Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.", "text_with_entity_marker": "Activation of [E1]interferon-gamma[/E1] inducing factor mediated by [E2]interleukin-1beta[/E2] converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[14, 30]], "entity_1_idx_in_text_with_entity_marker": [18, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta", "entity_2_idx": [[59, 76]], "entity_2_idx_in_text_with_entity_marker": [72, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1635_AIMed.d192.s1635.p2", "text": "Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.", "text_with_entity_marker": "Activation of [E1]interferon-gamma[/E1] inducing factor mediated by [E2]interleukin-1beta converting enzyme[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[14, 30]], "entity_1_idx_in_text_with_entity_marker": [18, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta converting enzyme", "entity_2_idx": [[59, 94]], "entity_2_idx_in_text_with_entity_marker": [72, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1635_AIMed.d192.s1635.p3", "text": "Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.", "text_with_entity_marker": "Activation of [E1]interferon-gamma inducing factor[/E1] mediated by [E2]interleukin-1beta[/E2] converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma inducing factor", "entity_1_idx": [[14, 46]], "entity_1_idx_in_text_with_entity_marker": [18, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta", "entity_2_idx": [[59, 76]], "entity_2_idx_in_text_with_entity_marker": [72, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1635_AIMed.d192.s1635.p4", "text": "Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.", "text_with_entity_marker": "Activation of [E1]interferon-gamma inducing factor[/E1] mediated by [E2]interleukin-1beta converting enzyme[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interferon-gamma inducing factor", "entity_1_idx": [[14, 46]], "entity_1_idx_in_text_with_entity_marker": [18, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta converting enzyme", "entity_2_idx": [[59, 94]], "entity_2_idx_in_text_with_entity_marker": [72, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1635_AIMed.d192.s1635.p5", "text": "Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.", "text_with_entity_marker": "Activation of interferon-gamma inducing factor mediated by [E1-E2]interleukin-1beta[/E1] converting enzyme[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta", "entity_1_idx": [[59, 76]], "entity_1_idx_in_text_with_entity_marker": [66, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta[/E1] converting enzyme", "entity_2_idx": [[59, 94]], "entity_2_idx_in_text_with_entity_marker": [66, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p0", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1]interleukin-1beta[/E1] ([E2]IL-1beta[/E2]) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta", "entity_1_idx": [[4, 21]], "entity_1_idx_in_text_with_entity_marker": [8, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[23, 31]], "entity_2_idx_in_text_with_entity_marker": [36, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p1", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1-E2]interleukin-1beta[/E1] (IL-1beta) converting enzyme[/E2] (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta", "entity_1_idx": [[4, 21]], "entity_1_idx_in_text_with_entity_marker": [11, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1beta[/E1] (IL-1beta) converting enzyme", "entity_2_idx": [[4, 50]], "entity_2_idx_in_text_with_entity_marker": [11, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p2", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1]interleukin-1beta[/E1] (IL-1beta) converting enzyme ([E2]ICE[/E2]) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin-1beta", "entity_1_idx": [[4, 21]], "entity_1_idx_in_text_with_entity_marker": [8, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ICE", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p3", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1]interleukin-1beta[/E1] (IL-1beta) converting enzyme (ICE) processes the inactive [E2]IL-1beta[/E2] precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta", "entity_1_idx": [[4, 21]], "entity_1_idx_in_text_with_entity_marker": [8, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[80, 88]], "entity_2_idx_in_text_with_entity_marker": [93, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p4", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1]interleukin-1beta (IL-1beta) converting enzyme[/E1][E2]IL-1beta[/E2]) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta (IL-1beta) converting enzyme", "entity_1_idx": [[4, 50]], "entity_1_idx_in_text_with_entity_marker": [8, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[23, 31]], "entity_2_idx_in_text_with_entity_marker": [63, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p5", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The interleukin-1beta ([E1]IL-1beta[/E1]) converting enzyme ([E2]ICE[/E2]) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1beta", "entity_1_idx": [[23, 31]], "entity_1_idx_in_text_with_entity_marker": [27, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ICE", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p6", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The interleukin-1beta ([E1]IL-1beta[/E1]) converting enzyme (ICE) processes the inactive [E2]IL-1beta[/E2] precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[23, 31]], "entity_1_idx_in_text_with_entity_marker": [27, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[80, 88]], "entity_2_idx_in_text_with_entity_marker": [93, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p7", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1]interleukin-1beta (IL-1beta) converting enzyme[/E1] ([E2]ICE[/E2]) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta (IL-1beta) converting enzyme", "entity_1_idx": [[4, 50]], "entity_1_idx_in_text_with_entity_marker": [8, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ICE", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p8", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The [E1]interleukin-1beta (IL-1beta) converting enzyme[/E1] (ICE) processes the inactive [E2]IL-1beta[/E2] precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1beta (IL-1beta) converting enzyme", "entity_1_idx": [[4, 50]], "entity_1_idx_in_text_with_entity_marker": [8, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[80, 88]], "entity_2_idx_in_text_with_entity_marker": [93, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1636_AIMed.d192.s1636.p9", "text": "The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine.", "text_with_entity_marker": "The interleukin-1beta (IL-1beta) converting enzyme ([E1]ICE[/E1]) processes the inactive [E2]IL-1beta[/E2] precursor to the proinflammatory cytokine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ICE", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[80, 88]], "entity_2_idx_in_text_with_entity_marker": [93, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p0", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "[E1]ICE[/E1] was also shown to cleave the precursor of [E2]interferon-gamma[/E2] inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ICE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon-gamma", "entity_2_idx": [[46, 62]], "entity_2_idx_in_text_with_entity_marker": [59, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p1", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "[E1]ICE[/E1] was also shown to cleave the precursor of [E2]interferon-gamma inducing factor[/E2] (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ICE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon-gamma inducing factor", "entity_2_idx": [[46, 78]], "entity_2_idx_in_text_with_entity_marker": [59, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p2", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "[E1]ICE[/E1] was also shown to cleave the precursor of interferon-gamma inducing factor ([E2]IGIF[/E2]) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ICE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[80, 84]], "entity_2_idx_in_text_with_entity_marker": [93, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p3", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "[E1]ICE[/E1] was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating [E2]IGIF[/E2] and facilitating its export.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ICE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p4", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "ICE was also shown to cleave the precursor of [E1-E2]interferon-gamma[/E1] inducing factor[/E2] (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[46, 62]], "entity_1_idx_in_text_with_entity_marker": [53, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interferon-gamma[/E1] inducing factor", "entity_2_idx": [[46, 78]], "entity_2_idx_in_text_with_entity_marker": [53, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p5", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "ICE was also shown to cleave the precursor of [E1]interferon-gamma[/E1] inducing factor ([E2]IGIF[/E2]) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[46, 62]], "entity_1_idx_in_text_with_entity_marker": [50, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[80, 84]], "entity_2_idx_in_text_with_entity_marker": [93, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p6", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "ICE was also shown to cleave the precursor of [E1]interferon-gamma[/E1] inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating [E2]IGIF[/E2] and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[46, 62]], "entity_1_idx_in_text_with_entity_marker": [50, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p7", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "ICE was also shown to cleave the precursor of [E1]interferon-gamma inducing factor[/E1] ([E2]IGIF[/E2]) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma inducing factor", "entity_1_idx": [[46, 78]], "entity_1_idx_in_text_with_entity_marker": [50, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[80, 84]], "entity_2_idx_in_text_with_entity_marker": [93, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p8", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "ICE was also shown to cleave the precursor of [E1]interferon-gamma inducing factor[/E1] (IGIF) at the authentic processing site with high efficiency, thereby activating [E2]IGIF[/E2] and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma inducing factor", "entity_1_idx": [[46, 78]], "entity_1_idx_in_text_with_entity_marker": [50, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1637_AIMed.d192.s1637.p9", "text": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export.", "text_with_entity_marker": "ICE was also shown to cleave the precursor of interferon-gamma inducing factor ([E1]IGIF[/E1]) at the authentic processing site with high efficiency, thereby activating [E2]IGIF[/E2] and facilitating its export.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGIF", "entity_1_idx": [[80, 84]], "entity_1_idx_in_text_with_entity_marker": [84, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1638_AIMed.d192.s1638.p0", "text": "Lipopolysaccharide-activated ICE-deficient (ICE-/-) Kupffer cells synthesized the IGIF precursor but failed to process it into the active form.", "text_with_entity_marker": "Lipopolysaccharide-activated [E1]ICE[/E1]-deficient (ICE-/-) Kupffer cells synthesized the [E2]IGIF[/E2] precursor but failed to process it into the active form.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ICE", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1639_AIMed.d192.s1639.p0", "text": "Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and [E2]IGIF[/E2] were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGIF", "entity_2_idx": [[21, 25]], "entity_2_idx_in_text_with_entity_marker": [34, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1639_AIMed.d192.s1639.p1", "text": "Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and IGIF were diminished in the sera of [E2]ICE[/E2]-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ICE", "entity_2_idx": [[57, 60]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d192.s1639_AIMed.d192.s1639.p2", "text": "Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.", "text_with_entity_marker": "Interferon-gamma and [E1]IGIF[/E1] were diminished in the sera of [E2]ICE[/E2]-/- mice exposed to Propionibacterium acnes and lipopolysaccharide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGIF", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ICE", "entity_2_idx": [[57, 60]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d188.s1595_AIMed.d188.s1595.p0", "text": "SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.", "text_with_entity_marker": "SREBP transcriptional activity is mediated through an interaction with the [E1-E2]CREB[/E1]-binding protein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CREB", "entity_1_idx": [[75, 79]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB[/E1]-binding protein", "entity_2_idx": [[75, 95]], "entity_2_idx_in_text_with_entity_marker": [82, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d188.s1598_AIMed.d188.s1598.p0", "text": "In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound SREBP-1 and SREBP-2.", "text_with_entity_marker": "In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound [E1]SREBP-1[/E1] and [E2]SREBP-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SREBP-1", "entity_1_idx": [[127, 134]], "entity_1_idx_in_text_with_entity_marker": [131, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SREBP-2", "entity_2_idx": [[139, 146]], "entity_2_idx_in_text_with_entity_marker": [152, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d188.s1599_AIMed.d188.s1599.p0", "text": "Peptide sequencing and Western blot analysis established that the 265-kD protein was CBP (CREB-binding protein),a recently identified transcriptional coactivator.", "text_with_entity_marker": "Peptide sequencing and Western blot analysis established that the 265-kD protein was [E1]CBP[/E1] ([E2]CREB-binding protein[/E2]),a recently identified transcriptional coactivator.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[85, 88]], "entity_1_idx_in_text_with_entity_marker": [89, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB-binding protein", "entity_2_idx": [[90, 110]], "entity_2_idx_in_text_with_entity_marker": [103, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d188.s1600_AIMed.d188.s1600.p0", "text": "The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).", "text_with_entity_marker": "The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant [E1]CBP[/E1] and [E2]p300[/E2] (a CBP-related protein).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p300", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d188.s1600_AIMed.d188.s1600.p1", "text": "The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).", "text_with_entity_marker": "The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant [E1]CBP[/E1] and p300 (a [E2]CBP[/E2]-related protein).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CBP", "entity_2_idx": [[128, 131]], "entity_2_idx_in_text_with_entity_marker": [141, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d188.s1600_AIMed.d188.s1600.p2", "text": "The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).", "text_with_entity_marker": "The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and [E1]p300[/E1] (a [E2]CBP[/E2]-related protein).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CBP", "entity_2_idx": [[128, 131]], "entity_2_idx_in_text_with_entity_marker": [141, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s955_AIMed.d113.s955.p0", "text": "Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity.", "text_with_entity_marker": "Cloning and functional analysis of [E1]BAG-1[/E1]: a novel [E2]Bcl-2[/E2]-binding protein with anti-cell death activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BAG-1", "entity_1_idx": [[35, 40]], "entity_1_idx_in_text_with_entity_marker": [39, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[50, 55]], "entity_2_idx_in_text_with_entity_marker": [63, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s955_AIMed.d113.s955.p1", "text": "Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity.", "text_with_entity_marker": "Cloning and functional analysis of [E1]BAG-1[/E1]: a novel [E2]Bcl-2-binding protein[/E2] with anti-cell death activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[35, 40]], "entity_1_idx_in_text_with_entity_marker": [39, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2-binding protein", "entity_2_idx": [[50, 71]], "entity_2_idx_in_text_with_entity_marker": [63, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s955_AIMed.d113.s955.p2", "text": "Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity.", "text_with_entity_marker": "Cloning and functional analysis of BAG-1: a novel [E1-E2]Bcl-2[/E1]-binding protein[/E2] with anti-cell death activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [57, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2[/E1]-binding protein", "entity_2_idx": [[50, 71]], "entity_2_idx_in_text_with_entity_marker": [57, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s956_AIMed.d113.s956.p0", "text": "Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1.", "text_with_entity_marker": "Using a protein interaction cloning technique, we identified cDNAs that encode a novel [E1-E2]Bcl-2[/E1]-binding protein[/E2], termed BAG-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2[/E1]-binding protein", "entity_2_idx": [[87, 108]], "entity_2_idx_in_text_with_entity_marker": [94, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s956_AIMed.d113.s956.p1", "text": "Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1.", "text_with_entity_marker": "Using a protein interaction cloning technique, we identified cDNAs that encode a novel [E1]Bcl-2[/E1]-binding protein, termed [E2]BAG-1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl-2", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BAG-1", "entity_2_idx": [[117, 122]], "entity_2_idx_in_text_with_entity_marker": [130, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s956_AIMed.d113.s956.p2", "text": "Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1.", "text_with_entity_marker": "Using a protein interaction cloning technique, we identified cDNAs that encode a novel [E1]Bcl-2-binding protein[/E1], termed [E2]BAG-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2-binding protein", "entity_1_idx": [[87, 108]], "entity_1_idx_in_text_with_entity_marker": [91, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BAG-1", "entity_2_idx": [[117, 122]], "entity_2_idx_in_text_with_entity_marker": [130, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s957_AIMed.d113.s957.p0", "text": "The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers.", "text_with_entity_marker": "The [E1]BAG-1[/E1] protein shares no significant homology with [E2]Bcl-2[/E2] or other Bcl-2 family proteins, which can form homo- and heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[54, 59]], "entity_2_idx_in_text_with_entity_marker": [67, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s957_AIMed.d113.s957.p1", "text": "The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers.", "text_with_entity_marker": "The [E1]BAG-1[/E1] protein shares no significant homology with Bcl-2 or other [E2]Bcl-2[/E2] family proteins, which can form homo- and heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s957_AIMed.d113.s957.p2", "text": "The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers.", "text_with_entity_marker": "The BAG-1 protein shares no significant homology with [E1]Bcl-2[/E1] or other [E2]Bcl-2[/E2] family proteins, which can form homo- and heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s958_AIMed.d113.s958.p0", "text": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "text_with_entity_marker": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of [E1]BAG-1[/E1] and [E2]Bcl-2[/E2] provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[97, 102]], "entity_2_idx_in_text_with_entity_marker": [110, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s958_AIMed.d113.s958.p1", "text": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "text_with_entity_marker": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of [E1]BAG-1[/E1] and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either [E2]BAG-1[/E2] or Bcl-2 protein alone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BAG-1", "entity_2_idx": [[330, 335]], "entity_2_idx_in_text_with_entity_marker": [343, 348], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s958_AIMed.d113.s958.p2", "text": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "text_with_entity_marker": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of [E1]BAG-1[/E1] and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or [E2]Bcl-2[/E2] protein alone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[339, 344]], "entity_2_idx_in_text_with_entity_marker": [352, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s958_AIMed.d113.s958.p3", "text": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "text_with_entity_marker": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and [E1]Bcl-2[/E1] provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either [E2]BAG-1[/E2] or Bcl-2 protein alone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BAG-1", "entity_2_idx": [[330, 335]], "entity_2_idx_in_text_with_entity_marker": [343, 348], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s958_AIMed.d113.s958.p4", "text": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "text_with_entity_marker": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and [E1]Bcl-2[/E1] provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or [E2]Bcl-2[/E2] protein alone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[339, 344]], "entity_2_idx_in_text_with_entity_marker": [352, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s958_AIMed.d113.s958.p5", "text": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone.", "text_with_entity_marker": "In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either [E1]BAG-1[/E1] or [E2]Bcl-2[/E2] protein alone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BAG-1", "entity_1_idx": [[330, 335]], "entity_1_idx_in_text_with_entity_marker": [334, 339], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[339, 344]], "entity_2_idx_in_text_with_entity_marker": [352, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s960_AIMed.d113.s960.p0", "text": "The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.", "text_with_entity_marker": "The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to [E1]Bcl-2[/E1]-independent pathways may instead reflect a need for the combination of [E2]Bcl-2[/E2] and BAG-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[154, 159]], "entity_1_idx_in_text_with_entity_marker": [158, 163], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bcl-2", "entity_2_idx": [[231, 236]], "entity_2_idx_in_text_with_entity_marker": [244, 249], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s960_AIMed.d113.s960.p1", "text": "The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.", "text_with_entity_marker": "The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to [E1]Bcl-2[/E1]-independent pathways may instead reflect a need for the combination of Bcl-2 and [E2]BAG-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[154, 159]], "entity_1_idx_in_text_with_entity_marker": [158, 163], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BAG-1", "entity_2_idx": [[241, 246]], "entity_2_idx_in_text_with_entity_marker": [254, 259], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d113.s960_AIMed.d113.s960.p2", "text": "The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.", "text_with_entity_marker": "The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-2-independent pathways may instead reflect a need for the combination of [E1]Bcl-2[/E1] and [E2]BAG-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl-2", "entity_1_idx": [[231, 236]], "entity_1_idx_in_text_with_entity_marker": [235, 240], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BAG-1", "entity_2_idx": [[241, 246]], "entity_2_idx_in_text_with_entity_marker": [254, 259], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d6.s50_AIMed.d6.s50.p0", "text": "Apoptotic proteins. p53 and c-myc related pathways.", "text_with_entity_marker": "Apoptotic proteins. [E1]p53[/E1] and [E2]c-myc[/E2] related pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-myc", "entity_2_idx": [[28, 33]], "entity_2_idx_in_text_with_entity_marker": [41, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d6.s51_AIMed.d6.s51.p0", "text": "c-Myc and p53 are two proteins that have critical roles in the regulation of apoptosis and the cell cycle.", "text_with_entity_marker": "[E1]c-Myc[/E1] and [E2]p53[/E2] are two proteins that have critical roles in the regulation of apoptosis and the cell cycle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Myc", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[10, 13]], "entity_2_idx_in_text_with_entity_marker": [23, 26], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1610_AIMed.d190.s1610.p0", "text": "Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.", "text_with_entity_marker": "Discrete protein interactions with the [E1]Grb2[/E1]/[E2]c-Cbl[/E2] complex in SCF- and TPO-mediated myeloid cell proliferation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1610_AIMed.d190.s1610.p1", "text": "Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.", "text_with_entity_marker": "Discrete protein interactions with the [E1]Grb2[/E1]/c-Cbl complex in [E2]SCF[/E2]- and TPO-mediated myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1610_AIMed.d190.s1610.p2", "text": "Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.", "text_with_entity_marker": "Discrete protein interactions with the [E1]Grb2[/E1]/c-Cbl complex in SCF- and [E2]TPO[/E2]-mediated myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1610_AIMed.d190.s1610.p3", "text": "Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.", "text_with_entity_marker": "Discrete protein interactions with the Grb2/[E1]c-Cbl[/E1] complex in [E2]SCF[/E2]- and TPO-mediated myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1610_AIMed.d190.s1610.p4", "text": "Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.", "text_with_entity_marker": "Discrete protein interactions with the Grb2/[E1]c-Cbl[/E1] complex in SCF- and [E2]TPO[/E2]-mediated myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1610_AIMed.d190.s1610.p5", "text": "Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.", "text_with_entity_marker": "Discrete protein interactions with the Grb2/c-Cbl complex in [E1]SCF[/E1]- and [E2]TPO[/E2]-mediated myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCF", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1611_AIMed.d190.s1611.p0", "text": "Hemopoietic cell proliferation is mediated by non-tyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the Grb2/c-Cbl.", "text_with_entity_marker": "Hemopoietic cell proliferation is mediated by non-tyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the [E1]Grb2[/E1]/[E2]c-Cbl[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[168, 172]], "entity_1_idx_in_text_with_entity_marker": [172, 176], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p0", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of [E1]c-Cbl[/E1] and the interaction of the [E2]Grb2[/E2]/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p1", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of [E1]c-Cbl[/E1] and the interaction of the Grb2/[E2]c-Cbl[/E2] complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[100, 105]], "entity_2_idx_in_text_with_entity_marker": [113, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p2", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of [E1]c-Cbl[/E1] and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine ([E2]c-Mpl[/E2]) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Mpl", "entity_2_idx": [[171, 176]], "entity_2_idx_in_text_with_entity_marker": [184, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p3", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of [E1]c-Cbl[/E1] and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase ([E2]c-Kit[/E2]) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p4", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the [E1]Grb2[/E1]/[E2]c-Cbl[/E2] complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[95, 99]], "entity_1_idx_in_text_with_entity_marker": [99, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[100, 105]], "entity_2_idx_in_text_with_entity_marker": [113, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p5", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the [E1]Grb2[/E1]/c-Cbl complex with signaling proteins upon activation of non-tyrosine ([E2]c-Mpl[/E2]) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[95, 99]], "entity_1_idx_in_text_with_entity_marker": [99, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Mpl", "entity_2_idx": [[171, 176]], "entity_2_idx_in_text_with_entity_marker": [184, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p6", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the [E1]Grb2[/E1]/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase ([E2]c-Kit[/E2]) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[95, 99]], "entity_1_idx_in_text_with_entity_marker": [99, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p7", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/[E1]c-Cbl[/E1] complex with signaling proteins upon activation of non-tyrosine ([E2]c-Mpl[/E2]) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[100, 105]], "entity_1_idx_in_text_with_entity_marker": [104, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Mpl", "entity_2_idx": [[171, 176]], "entity_2_idx_in_text_with_entity_marker": [184, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p8", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/[E1]c-Cbl[/E1] complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase ([E2]c-Kit[/E2]) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[100, 105]], "entity_1_idx_in_text_with_entity_marker": [104, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1612_AIMed.d190.s1612.p9", "text": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation.", "text_with_entity_marker": "In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine ([E1]c-Mpl[/E1]) and tyrosine kinase ([E2]c-Kit[/E2]) receptors leading to myeloid cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Mpl", "entity_1_idx": [[171, 176]], "entity_1_idx_in_text_with_entity_marker": [175, 180], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p0", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both [E1]c-Mpl[/E1] and [E2]c-Kit[/E2] ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Mpl", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[83, 88]], "entity_2_idx_in_text_with_entity_marker": [96, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p1", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both [E1]c-Mpl[/E1] and c-Kit ligands, namely: [E2]SCF[/E2] and TPO, induce c-Cbl tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Mpl", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p2", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both [E1]c-Mpl[/E1] and c-Kit ligands, namely: SCF and [E2]TPO[/E2], induce c-Cbl tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Mpl", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p3", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both [E1]c-Mpl[/E1] and c-Kit ligands, namely: SCF and TPO, induce [E2]c-Cbl[/E2] tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Mpl", "entity_1_idx": [[73, 78]], "entity_1_idx_in_text_with_entity_marker": [77, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p4", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and [E1]c-Kit[/E1] ligands, namely: [E2]SCF[/E2] and TPO, induce c-Cbl tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Kit", "entity_1_idx": [[83, 88]], "entity_1_idx_in_text_with_entity_marker": [87, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p5", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and [E1]c-Kit[/E1] ligands, namely: SCF and [E2]TPO[/E2], induce c-Cbl tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Kit", "entity_1_idx": [[83, 88]], "entity_1_idx_in_text_with_entity_marker": [87, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p6", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and [E1]c-Kit[/E1] ligands, namely: SCF and TPO, induce [E2]c-Cbl[/E2] tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Kit", "entity_1_idx": [[83, 88]], "entity_1_idx_in_text_with_entity_marker": [87, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p7", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: [E1]SCF[/E1] and [E2]TPO[/E2], induce c-Cbl tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCF", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p8", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: [E1]SCF[/E1] and TPO, induce [E2]c-Cbl[/E2] tyrosine phosphorylation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SCF", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1613_AIMed.d190.s1613.p9", "text": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation.", "text_with_entity_marker": "By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and [E1]TPO[/E1], induce [E2]c-Cbl[/E2] tyrosine phosphorylation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TPO", "entity_1_idx": [[114, 117]], "entity_1_idx_in_text_with_entity_marker": [118, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1614_AIMed.d190.s1614.p0", "text": "In these cells the adaptor protein Grb2 constitutively binds a substantial fraction of c-Cbl through the N-terminal SH3 domain.", "text_with_entity_marker": "In these cells the adaptor protein [E1]Grb2[/E1] constitutively binds a substantial fraction of [E2]c-Cbl[/E2] through the N-terminal SH3 domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[35, 39]], "entity_1_idx_in_text_with_entity_marker": [39, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p0", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable [E1]Grb2[/E1]/[E2]c-Cbl[/E2] complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p1", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable [E1]Grb2[/E1]/c-Cbl complex interacts, through the [E2]Grb2[/E2] SH2 domain, with the SCF-activated c-Kit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p2", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable [E1]Grb2[/E1]/c-Cbl complex interacts, through the Grb2 SH2 domain, with the [E2]SCF[/E2]-activated c-Kit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p3", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable [E1]Grb2[/E1]/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated [E2]c-Kit[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p4", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable Grb2/[E1]c-Cbl[/E1] complex interacts, through the [E2]Grb2[/E2] SH2 domain, with the SCF-activated c-Kit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p5", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable Grb2/[E1]c-Cbl[/E1] complex interacts, through the Grb2 SH2 domain, with the [E2]SCF[/E2]-activated c-Kit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p6", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable Grb2/[E1]c-Cbl[/E1] complex interacts, through the Grb2 SH2 domain, with the SCF-activated [E2]c-Kit[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p7", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the [E1]Grb2[/E1] SH2 domain, with the [E2]SCF[/E2]-activated c-Kit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[86, 90]], "entity_1_idx_in_text_with_entity_marker": [90, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SCF", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p8", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the [E1]Grb2[/E1] SH2 domain, with the SCF-activated [E2]c-Kit[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[86, 90]], "entity_1_idx_in_text_with_entity_marker": [90, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1615_AIMed.d190.s1615.p9", "text": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit.", "text_with_entity_marker": "In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the [E1]SCF[/E1]-activated [E2]c-Kit[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SCF", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1616_AIMed.d190.s1616.p0", "text": "By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2.", "text_with_entity_marker": "By contrast stimulation with [E1]TPO[/E1] leads to the formation of a [E2]Grb2[/E2] complex containing JAK2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TPO", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1616_AIMed.d190.s1616.p1", "text": "By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2.", "text_with_entity_marker": "By contrast stimulation with [E1]TPO[/E1] leads to the formation of a Grb2 complex containing [E2]JAK2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TPO", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[85, 89]], "entity_2_idx_in_text_with_entity_marker": [98, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1616_AIMed.d190.s1616.p2", "text": "By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2.", "text_with_entity_marker": "By contrast stimulation with TPO leads to the formation of a [E1]Grb2[/E1] complex containing [E2]JAK2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[85, 89]], "entity_2_idx_in_text_with_entity_marker": [98, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1617_AIMed.d190.s1617.p0", "text": "In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl.", "text_with_entity_marker": "In vitro and in vivo experiments support the hypothesis that [E1]Grb2[/E1] mediates the association of [E2]c-Kit[/E2] with c-Cbl.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Kit", "entity_2_idx": [[94, 99]], "entity_2_idx_in_text_with_entity_marker": [107, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1617_AIMed.d190.s1617.p1", "text": "In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl.", "text_with_entity_marker": "In vitro and in vivo experiments support the hypothesis that [E1]Grb2[/E1] mediates the association of c-Kit with [E2]c-Cbl[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1617_AIMed.d190.s1617.p2", "text": "In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl.", "text_with_entity_marker": "In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of [E1]c-Kit[/E1] with [E2]c-Cbl[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Kit", "entity_1_idx": [[94, 99]], "entity_1_idx_in_text_with_entity_marker": [98, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p0", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon [E1]SCF[/E1] stimulation, the [E2]Grb2[/E2]/c-Cbl complex recruits Shc, probably via Grb2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCF", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[50, 54]], "entity_2_idx_in_text_with_entity_marker": [63, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p1", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon [E1]SCF[/E1] stimulation, the Grb2/[E2]c-Cbl[/E2] complex recruits Shc, probably via Grb2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCF", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p2", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon [E1]SCF[/E1] stimulation, the Grb2/c-Cbl complex recruits [E2]Shc[/E2], probably via Grb2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCF", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p3", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon [E1]SCF[/E1] stimulation, the Grb2/c-Cbl complex recruits Shc, probably via [E2]Grb2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SCF", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p4", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon SCF stimulation, the [E1]Grb2[/E1]/[E2]c-Cbl[/E2] complex recruits Shc, probably via Grb2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p5", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon SCF stimulation, the [E1]Grb2[/E1]/c-Cbl complex recruits [E2]Shc[/E2], probably via Grb2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p6", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon SCF stimulation, the [E1]Grb2[/E1]/c-Cbl complex recruits Shc, probably via [E2]Grb2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p7", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon SCF stimulation, the Grb2/[E1]c-Cbl[/E1] complex recruits [E2]Shc[/E2], probably via Grb2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p8", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon SCF stimulation, the Grb2/[E1]c-Cbl[/E1] complex recruits Shc, probably via [E2]Grb2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1618_AIMed.d190.s1618.p9", "text": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits Shc, probably via Grb2.", "text_with_entity_marker": "Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits [E1]Shc[/E1], probably via [E2]Grb2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Shc", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p0", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the [E1]Ras[/E1] exchanger factor ([E2]Sos1[/E2]) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sos1", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [51, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p1", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the [E1]Ras[/E1] exchanger factor (Sos1) was not detected in anti-[E2]c-Cbl[/E2] immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p2", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the [E1]Ras[/E1] exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that [E2]Grb2[/E2]/Sos1 and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[110, 114]], "entity_2_idx_in_text_with_entity_marker": [123, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p3", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the [E1]Ras[/E1] exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/[E2]Sos1[/E2] and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sos1", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p4", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the [E1]Ras[/E1] exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and [E2]Grb2[/E2]/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p5", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the [E1]Ras[/E1] exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/[E2]c-Cbl[/E2] are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p6", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor ([E1]Sos1[/E1]) was not detected in anti-[E2]c-Cbl[/E2] immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p7", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor ([E1]Sos1[/E1]) was not detected in anti-c-Cbl immunoprecipitates suggesting that [E2]Grb2[/E2]/Sos1 and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[110, 114]], "entity_2_idx_in_text_with_entity_marker": [123, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p8", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor ([E1]Sos1[/E1]) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/[E2]Sos1[/E2] and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sos1", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p9", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor ([E1]Sos1[/E1]) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and [E2]Grb2[/E2]/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p10", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor ([E1]Sos1[/E1]) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/[E2]c-Cbl[/E2] are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p11", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-[E1]c-Cbl[/E1] immunoprecipitates suggesting that [E2]Grb2[/E2]/Sos1 and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[110, 114]], "entity_2_idx_in_text_with_entity_marker": [123, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p12", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-[E1]c-Cbl[/E1] immunoprecipitates suggesting that Grb2/[E2]Sos1[/E2] and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sos1", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p13", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-[E1]c-Cbl[/E1] immunoprecipitates suggesting that Grb2/Sos1 and [E2]Grb2[/E2]/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p14", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-[E1]c-Cbl[/E1] immunoprecipitates suggesting that Grb2/Sos1 and Grb2/[E2]c-Cbl[/E2] are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p15", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that [E1]Grb2[/E1]/[E2]Sos1[/E2] and Grb2/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sos1", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p16", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that [E1]Grb2[/E1]/Sos1 and [E2]Grb2[/E2]/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p17", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that [E1]Grb2[/E1]/Sos1 and Grb2/[E2]c-Cbl[/E2] are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p18", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/[E1]Sos1[/E1] and [E2]Grb2[/E2]/c-Cbl are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p19", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/[E1]Sos1[/E1] and Grb2/[E2]c-Cbl[/E2] are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos1", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1619_AIMed.d190.s1619.p20", "text": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes.", "text_with_entity_marker": "By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and [E1]Grb2[/E1]/[E2]c-Cbl[/E2] are present in different complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[124, 128]], "entity_1_idx_in_text_with_entity_marker": [128, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1620_AIMed.d190.s1620.p0", "text": "Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.", "text_with_entity_marker": "Taken together our results demonstrate that [E1]c-Cbl[/E1] plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with [E2]Grb2[/E2]/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[220, 224]], "entity_2_idx_in_text_with_entity_marker": [233, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1620_AIMed.d190.s1620.p1", "text": "Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.", "text_with_entity_marker": "Taken together our results demonstrate that [E1]c-Cbl[/E1] plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/[E2]c-Cbl[/E2] complex when non-tyrosine or tyrosine kinase receptors are activated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[225, 230]], "entity_2_idx_in_text_with_entity_marker": [238, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d190.s1620_AIMed.d190.s1620.p2", "text": "Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.", "text_with_entity_marker": "Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with [E1]Grb2[/E1]/[E2]c-Cbl[/E2] complex when non-tyrosine or tyrosine kinase receptors are activated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Grb2", "entity_1_idx": [[220, 224]], "entity_1_idx_in_text_with_entity_marker": [224, 228], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[225, 230]], "entity_2_idx_in_text_with_entity_marker": [238, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s203_AIMed.d25.s203.p0", "text": "Assaying of tumor necrosis factor alpha, complement factors, and alpha-1-antitrypsin in the diagnosis of malignant serous effusions.", "text_with_entity_marker": "Assaying of [E1]tumor necrosis factor alpha[/E1], complement factors, and [E2]alpha-1-antitrypsin[/E2] in the diagnosis of malignant serous effusions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor alpha", "entity_1_idx": [[12, 39]], "entity_1_idx_in_text_with_entity_marker": [16, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[65, 84]], "entity_2_idx_in_text_with_entity_marker": [78, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p0", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] ([E2]TNFalpha[/E2]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p1", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E2]TNFalpha[/E2], alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[182, 190]], "entity_2_idx_in_text_with_entity_marker": [195, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p2", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E2]alpha-1-antitrypsin[/E2] (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[192, 211]], "entity_2_idx_in_text_with_entity_marker": [205, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p3", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p4", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p5", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p6", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether [E2]TNFalpha[/E2], alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[182, 190]], "entity_2_idx_in_text_with_entity_marker": [195, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p7", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E2]alpha-1-antitrypsin[/E2] (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[192, 211]], "entity_2_idx_in_text_with_entity_marker": [205, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p8", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p9", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p10", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p11", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], [E2]alpha-1-antitrypsin[/E2] (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[192, 211]], "entity_2_idx_in_text_with_entity_marker": [205, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p12", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], alpha-1-antitrypsin ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p13", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], alpha-1-antitrypsin (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p14", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], alpha-1-antitrypsin (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p15", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E1]alpha-1-antitrypsin[/E1] ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-1-antitrypsin", "entity_1_idx": [[192, 211]], "entity_1_idx_in_text_with_entity_marker": [196, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p16", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E1]alpha-1-antitrypsin[/E1] (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-1-antitrypsin", "entity_1_idx": [[192, 211]], "entity_1_idx_in_text_with_entity_marker": [196, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p17", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E1]alpha-1-antitrypsin[/E1] (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha-1-antitrypsin", "entity_1_idx": [[192, 211]], "entity_1_idx_in_text_with_entity_marker": [196, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p18", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E1]alpha1AT[/E1]), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[213, 221]], "entity_1_idx_in_text_with_entity_marker": [217, 225], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p19", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E1]alpha1AT[/E1]), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[213, 221]], "entity_1_idx_in_text_with_entity_marker": [217, 225], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p20", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors [E1]C3[/E1] and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C3", "entity_1_idx": [[247, 249]], "entity_1_idx_in_text_with_entity_marker": [251, 253], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p0", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "[E1]TNFalpha[/E1], [E2]alpha1AT[/E2], and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[10, 18]], "entity_2_idx_in_text_with_entity_marker": [23, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p1", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "[E1]TNFalpha[/E1], alpha1AT, and complement factors [E2]C3[/E2] and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[43, 45]], "entity_2_idx_in_text_with_entity_marker": [56, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p2", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "[E1]TNFalpha[/E1], alpha1AT, and complement factors C3 and [E2]C4[/E2] concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[50, 52]], "entity_2_idx_in_text_with_entity_marker": [63, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p3", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "TNFalpha, [E1]alpha1AT[/E1], and complement factors [E2]C3[/E2] and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[10, 18]], "entity_1_idx_in_text_with_entity_marker": [14, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[43, 45]], "entity_2_idx_in_text_with_entity_marker": [56, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p4", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "TNFalpha, [E1]alpha1AT[/E1], and complement factors C3 and [E2]C4[/E2] concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[10, 18]], "entity_1_idx_in_text_with_entity_marker": [14, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[50, 52]], "entity_2_idx_in_text_with_entity_marker": [63, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p5", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "TNFalpha, alpha1AT, and complement factors [E1]C3[/E1] and [E2]C4[/E2] concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C3", "entity_1_idx": [[43, 45]], "entity_1_idx_in_text_with_entity_marker": [47, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[50, 52]], "entity_2_idx_in_text_with_entity_marker": [63, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p0", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was [E1]alpha1AT[/E1] effusion, [E2]C4[/E2] serum, TNFalpha-effusion, and C3 effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[29, 37]], "entity_1_idx_in_text_with_entity_marker": [33, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[48, 50]], "entity_2_idx_in_text_with_entity_marker": [61, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p1", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was [E1]alpha1AT[/E1] effusion, C4 serum, [E2]TNFalpha[/E2]-effusion, and C3 effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[29, 37]], "entity_1_idx_in_text_with_entity_marker": [33, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[58, 66]], "entity_2_idx_in_text_with_entity_marker": [71, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p2", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was [E1]alpha1AT[/E1] effusion, C4 serum, TNFalpha-effusion, and [E2]C3[/E2] effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1AT", "entity_1_idx": [[29, 37]], "entity_1_idx_in_text_with_entity_marker": [33, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[81, 83]], "entity_2_idx_in_text_with_entity_marker": [94, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p3", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was alpha1AT effusion, [E1]C4[/E1] serum, [E2]TNFalpha[/E2]-effusion, and C3 effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C4", "entity_1_idx": [[48, 50]], "entity_1_idx_in_text_with_entity_marker": [52, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[58, 66]], "entity_2_idx_in_text_with_entity_marker": [71, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p4", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was alpha1AT effusion, [E1]C4[/E1] serum, TNFalpha-effusion, and [E2]C3[/E2] effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C4", "entity_1_idx": [[48, 50]], "entity_1_idx_in_text_with_entity_marker": [52, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[81, 83]], "entity_2_idx_in_text_with_entity_marker": [94, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p5", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was alpha1AT effusion, C4 serum, [E1]TNFalpha[/E1]-effusion, and [E2]C3[/E2] effusion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[58, 66]], "entity_1_idx_in_text_with_entity_marker": [62, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[81, 83]], "entity_2_idx_in_text_with_entity_marker": [94, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p0", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of [E1]TNFalpha[/E1], complement factors [E2]C3[/E2] and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[46, 48]], "entity_2_idx_in_text_with_entity_marker": [59, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p1", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of [E1]TNFalpha[/E1], complement factors C3 and [E2]C4[/E2], and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[53, 55]], "entity_2_idx_in_text_with_entity_marker": [66, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p2", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of [E1]TNFalpha[/E1], complement factors C3 and C4, and [E2]alpha1AT[/E2] may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFalpha", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p3", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of TNFalpha, complement factors [E1]C3[/E1] and [E2]C4[/E2], and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C3", "entity_1_idx": [[46, 48]], "entity_1_idx_in_text_with_entity_marker": [50, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[53, 55]], "entity_2_idx_in_text_with_entity_marker": [66, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p4", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of TNFalpha, complement factors [E1]C3[/E1] and C4, and [E2]alpha1AT[/E2] may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C3", "entity_1_idx": [[46, 48]], "entity_1_idx_in_text_with_entity_marker": [50, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p5", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of TNFalpha, complement factors C3 and [E1]C4[/E1], and [E2]alpha1AT[/E2] may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "C4", "entity_1_idx": [[53, 55]], "entity_1_idx_in_text_with_entity_marker": [57, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1230_AIMed.d146.s1230.p0", "text": "Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.", "text_with_entity_marker": "Characterization of a novel high affinity human [E1-E2]IL-7[/E1] receptor[/E2]. Expression on T cells and association with IL-7 driven proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [55, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7[/E1] receptor", "entity_2_idx": [[48, 61]], "entity_2_idx_in_text_with_entity_marker": [55, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1230_AIMed.d146.s1230.p1", "text": "Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.", "text_with_entity_marker": "Characterization of a novel high affinity human [E1]IL-7[/E1] receptor. Expression on T cells and association with [E2]IL-7[/E2] driven proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [52, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1230_AIMed.d146.s1230.p2", "text": "Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.", "text_with_entity_marker": "Characterization of a novel high affinity human [E1]IL-7 receptor[/E1]. Expression on T cells and association with [E2]IL-7[/E2] driven proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7 receptor", "entity_1_idx": [[48, 61]], "entity_1_idx_in_text_with_entity_marker": [52, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1233_AIMed.d146.s1233.p0", "text": "We have previously demonstrated such changes by affinity cross-linking studies, and have shown that unstimulated human T cells express a single IL-7R of 90 kDa, whereas activated T cells express an additional 76-kDa IL-7 binding protein.", "text_with_entity_marker": "We have previously demonstrated such changes by affinity cross-linking studies, and have shown that unstimulated human T cells express a single [E1]IL-7R[/E1] of 90 kDa, whereas activated T cells express an additional 76-kDa [E2]IL-7[/E2] binding protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[144, 149]], "entity_1_idx_in_text_with_entity_marker": [148, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[216, 220]], "entity_2_idx_in_text_with_entity_marker": [229, 233], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1234_AIMed.d146.s1234.p0", "text": "In this study the origin and function of the p90 and p76 molecules have been investigated.", "text_with_entity_marker": "In this study the origin and function of the [E1]p90[/E1] and [E2]p76[/E2] molecules have been investigated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1235_AIMed.d146.s1235.p0", "text": "To determine the role of each of these receptors in IL-7 driven proliferation, IL-7R expression and proliferative capacity were monitored during mitogenic stimulation.", "text_with_entity_marker": "To determine the role of each of these receptors in [E1]IL-7[/E1] driven proliferation, [E2]IL-7R[/E2] expression and proliferative capacity were monitored during mitogenic stimulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[79, 84]], "entity_2_idx_in_text_with_entity_marker": [92, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p0", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the [E2]p76[/E2] IL-7R, and not with expression of the p90 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p1", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the p76 [E2]IL-7R[/E2], and not with expression of the p90 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p2", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the p76 IL-7R, and not with expression of the [E2]p90[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p3", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the p76 IL-7R, and not with expression of the p90 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p4", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the [E1]p76[/E1] [E2]IL-7R[/E2], and not with expression of the p90 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p5", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the [E1]p76[/E1] IL-7R, and not with expression of the [E2]p90[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p6", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the [E1]p76[/E1] IL-7R, and not with expression of the p90 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p7", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 [E1]IL-7R[/E1], and not with expression of the [E2]p90[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p8", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 [E1]IL-7R[/E1], and not with expression of the p90 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p9", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the [E1]p90[/E1] [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p0", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "[E1]IL-7[/E1]-driven proliferation is mediated via high affinity [E2]IL-7R[/E2], and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[56, 61]], "entity_2_idx_in_text_with_entity_marker": [69, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p1", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "[E1]IL-7[/E1]-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the [E2]p90[/E2] IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p2", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "[E1]IL-7[/E1]-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 [E2]IL-7R[/E2], the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[127, 132]], "entity_2_idx_in_text_with_entity_marker": [140, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p3", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "[E1]IL-7[/E1]-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the [E2]p76[/E2] IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p4", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "[E1]IL-7[/E1]-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 [E2]IL-7R[/E2] bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p5", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "[E1]IL-7[/E1]-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound [E2]IL-7[/E2] with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p6", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity [E1]IL-7R[/E1], and accordingly, Scatchard analysis revealed that, like the [E2]p90[/E2] IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[56, 61]], "entity_1_idx_in_text_with_entity_marker": [60, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p7", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity [E1]IL-7R[/E1], and accordingly, Scatchard analysis revealed that, like the p90 [E2]IL-7R[/E2], the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[56, 61]], "entity_1_idx_in_text_with_entity_marker": [60, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[127, 132]], "entity_2_idx_in_text_with_entity_marker": [140, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p8", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity [E1]IL-7R[/E1], and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the [E2]p76[/E2] IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[56, 61]], "entity_1_idx_in_text_with_entity_marker": [60, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p9", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity [E1]IL-7R[/E1], and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 [E2]IL-7R[/E2] bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[56, 61]], "entity_1_idx_in_text_with_entity_marker": [60, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p10", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity [E1]IL-7R[/E1], and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound [E2]IL-7[/E2] with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[56, 61]], "entity_1_idx_in_text_with_entity_marker": [60, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p11", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the [E1]p90[/E1] [E2]IL-7R[/E2], the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[123, 126]], "entity_1_idx_in_text_with_entity_marker": [127, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[127, 132]], "entity_2_idx_in_text_with_entity_marker": [140, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p12", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the [E1]p90[/E1] IL-7R, the [E2]p76[/E2] IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[123, 126]], "entity_1_idx_in_text_with_entity_marker": [127, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p13", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the [E1]p90[/E1] IL-7R, the p76 [E2]IL-7R[/E2] bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[123, 126]], "entity_1_idx_in_text_with_entity_marker": [127, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p14", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the [E1]p90[/E1] IL-7R, the p76 IL-7R bound [E2]IL-7[/E2] with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[123, 126]], "entity_1_idx_in_text_with_entity_marker": [127, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p15", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 [E1]IL-7R[/E1], the [E2]p76[/E2] IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[127, 132]], "entity_1_idx_in_text_with_entity_marker": [131, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p16", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 [E1]IL-7R[/E1], the p76 [E2]IL-7R[/E2] bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[127, 132]], "entity_1_idx_in_text_with_entity_marker": [131, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p17", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 [E1]IL-7R[/E1], the p76 IL-7R bound [E2]IL-7[/E2] with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[127, 132]], "entity_1_idx_in_text_with_entity_marker": [131, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p18", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the [E1]p76[/E1] [E2]IL-7R[/E2] bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[138, 141]], "entity_1_idx_in_text_with_entity_marker": [142, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p19", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the [E1]p76[/E1] IL-7R bound [E2]IL-7[/E2] with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[138, 141]], "entity_1_idx_in_text_with_entity_marker": [142, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1237_AIMed.d146.s1237.p20", "text": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "text_with_entity_marker": "IL-7-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 [E1]IL-7R[/E1] bound [E2]IL-7[/E2] with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[142, 147]], "entity_1_idx_in_text_with_entity_marker": [146, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1238_AIMed.d146.s1238.p0", "text": "Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.", "text_with_entity_marker": "Deglycosylation studies showed that the [E1]p90[/E1] and [E2]p76[/E2] IL-7R are not simply differently glycosylated isoforms of a single receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[48, 51]], "entity_2_idx_in_text_with_entity_marker": [61, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1238_AIMed.d146.s1238.p1", "text": "Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.", "text_with_entity_marker": "Deglycosylation studies showed that the [E1]p90[/E1] and p76 [E2]IL-7R[/E2] are not simply differently glycosylated isoforms of a single receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[52, 57]], "entity_2_idx_in_text_with_entity_marker": [65, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1238_AIMed.d146.s1238.p2", "text": "Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.", "text_with_entity_marker": "Deglycosylation studies showed that the p90 and [E1]p76[/E1] [E2]IL-7R[/E2] are not simply differently glycosylated isoforms of a single receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[52, 57]], "entity_2_idx_in_text_with_entity_marker": [65, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p0", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the [E2]p90[/E2] IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p1", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the p90 [E2]IL-7R[/E2] but not T-cell clones that express predominantly the p76 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p2", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the [E2]p76[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[175, 178]], "entity_2_idx_in_text_with_entity_marker": [188, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p3", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p4", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the [E1]p90[/E1] [E2]IL-7R[/E2] but not T-cell clones that express predominantly the p76 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p5", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the [E1]p90[/E1] IL-7R but not T-cell clones that express predominantly the [E2]p76[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[175, 178]], "entity_2_idx_in_text_with_entity_marker": [188, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p6", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the [E1]p90[/E1] IL-7R but not T-cell clones that express predominantly the p76 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p7", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 [E1]IL-7R[/E1] but not T-cell clones that express predominantly the [E2]p76[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[175, 178]], "entity_2_idx_in_text_with_entity_marker": [188, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p8", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 [E1]IL-7R[/E1] but not T-cell clones that express predominantly the p76 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p9", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the [E1]p76[/E1] [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[175, 178]], "entity_1_idx_in_text_with_entity_marker": [179, 182], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1240_AIMed.d146.s1240.p0", "text": "These antibodies also immunoprecipitated the cloned IL-7R as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa IL-7R.", "text_with_entity_marker": "These antibodies also immunoprecipitated the cloned [E1]IL-7R[/E1] as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[183, 188]], "entity_2_idx_in_text_with_entity_marker": [196, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p0", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned [E2]IL-7R[/E2], thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p1", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the [E2]p76[/E2] IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[168, 171]], "entity_2_idx_in_text_with_entity_marker": [181, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p2", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 [E2]IL-7R[/E2] is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p3", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p4", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned [E1]IL-7R[/E1], thereby excluding the possibility that the [E2]p76[/E2] IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[118, 123]], "entity_1_idx_in_text_with_entity_marker": [122, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[168, 171]], "entity_2_idx_in_text_with_entity_marker": [181, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p5", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned [E1]IL-7R[/E1], thereby excluding the possibility that the p76 [E2]IL-7R[/E2] is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[118, 123]], "entity_1_idx_in_text_with_entity_marker": [122, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p6", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned [E1]IL-7R[/E1], thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[118, 123]], "entity_1_idx_in_text_with_entity_marker": [122, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p7", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the [E1]p76[/E1] [E2]IL-7R[/E2] is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[168, 171]], "entity_1_idx_in_text_with_entity_marker": [172, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p8", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the [E1]p76[/E1] IL-7R is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[168, 171]], "entity_1_idx_in_text_with_entity_marker": [172, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p9", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 [E1]IL-7R[/E1] is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[172, 177]], "entity_1_idx_in_text_with_entity_marker": [176, 181], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p0", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] [E2]IL-7R[/E2] is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p1", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned [E2]IL-7R[/E2], and imply that the p90 and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[80, 85]], "entity_2_idx_in_text_with_entity_marker": [93, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p2", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the [E2]p90[/E2] and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p3", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p4", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p5", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned [E2]IL-7R[/E2], and imply that the p90 and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[80, 85]], "entity_2_idx_in_text_with_entity_marker": [93, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p6", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned IL-7R, and imply that the [E2]p90[/E2] and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p7", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned IL-7R, and imply that the p90 and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p8", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p9", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned [E1]IL-7R[/E1], and imply that the [E2]p90[/E2] and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p10", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned [E1]IL-7R[/E1], and imply that the p90 and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p11", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned [E1]IL-7R[/E1], and imply that the p90 and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p12", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the [E1]p90[/E1] and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p13", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the [E1]p90[/E1] and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p90", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p14", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and [E1]p76[/E1] [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p76", "entity_1_idx": [[114, 117]], "entity_1_idx_in_text_with_entity_marker": [118, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1243_AIMed.d146.s1243.p0", "text": "Taken together these data suggest that the 76-kDa receptor is a novel high affinity IL-7R that may be necessary for IL-7 driven proliferation in human T cells.", "text_with_entity_marker": "Taken together these data suggest that the 76-kDa receptor is a novel high affinity [E1]IL-7R[/E1] that may be necessary for [E2]IL-7[/E2] driven proliferation in human T cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7R", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1251_AIMed.d148.s1251.p0", "text": "Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein", "text_with_entity_marker": "Two potentially oncogenic cyclins, [E1]cyclin A[/E1] and [E2]cyclin D1[/E2], share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[35, 43]], "entity_1_idx_in_text_with_entity_marker": [39, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[48, 57]], "entity_2_idx_in_text_with_entity_marker": [61, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1251_AIMed.d148.s1251.p1", "text": "Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein", "text_with_entity_marker": "Two potentially oncogenic cyclins, [E1]cyclin A[/E1] and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the [E2]Rb[/E2] protein", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[35, 43]], "entity_1_idx_in_text_with_entity_marker": [39, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[168, 170]], "entity_2_idx_in_text_with_entity_marker": [181, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1251_AIMed.d148.s1251.p2", "text": "Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein", "text_with_entity_marker": "Two potentially oncogenic cyclins, cyclin A and [E1]cyclin D1[/E1], share common properties of subunit configuration, tyrosine phosphorylation and physical association with the [E2]Rb[/E2] protein", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D1", "entity_1_idx": [[48, 57]], "entity_1_idx_in_text_with_entity_marker": [52, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[168, 170]], "entity_2_idx_in_text_with_entity_marker": [181, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1252_AIMed.d148.s1252.p0", "text": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.", "text_with_entity_marker": ".Originally identified as a 'mitotic cyclin', [E1]cyclin A[/E1] exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an [E2]S-phase-promoting factor[/E2] (SPF) as well as a candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[46, 54]], "entity_1_idx_in_text_with_entity_marker": [50, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "S-phase-promoting factor", "entity_2_idx": [[227, 251]], "entity_2_idx_in_text_with_entity_marker": [240, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1252_AIMed.d148.s1252.p1", "text": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.", "text_with_entity_marker": ".Originally identified as a 'mitotic cyclin', [E1]cyclin A[/E1] exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor ([E2]SPF[/E2]) as well as a candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin A", "entity_1_idx": [[46, 54]], "entity_1_idx_in_text_with_entity_marker": [50, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SPF", "entity_2_idx": [[253, 256]], "entity_2_idx_in_text_with_entity_marker": [266, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1252_AIMed.d148.s1252.p2", "text": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.", "text_with_entity_marker": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an [E1]S-phase-promoting factor[/E1] ([E2]SPF[/E2]) as well as a candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "S-phase-promoting factor", "entity_1_idx": [[227, 251]], "entity_1_idx_in_text_with_entity_marker": [231, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SPF", "entity_2_idx": [[253, 256]], "entity_2_idx_in_text_with_entity_marker": [266, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1253_AIMed.d148.s1253.p0", "text": "Other recent studies have identified human cyclin D1 (PRAD1) as a putative G1 cyclin and candidate proto-oncogene.", "text_with_entity_marker": "Other recent studies have identified human [E1]cyclin D1[/E1] ([E2]PRAD1[/E2]) as a putative G1 cyclin and candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[43, 52]], "entity_1_idx_in_text_with_entity_marker": [47, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PRAD1", "entity_2_idx": [[54, 59]], "entity_2_idx_in_text_with_entity_marker": [67, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1257_AIMed.d148.s1257.p0", "text": "Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro.", "text_with_entity_marker": "Moreover, [E1]cyclin D1[/E1] was found to be phosphorylated on tyrosine residues in vivo and, like [E2]cyclin A[/E2], was readily phosphorylated by pp60c-src in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[90, 98]], "entity_2_idx_in_text_with_entity_marker": [103, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1257_AIMed.d148.s1257.p1", "text": "Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro.", "text_with_entity_marker": "Moreover, [E1]cyclin D1[/E1] was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by [E2]pp60c-src[/E2] in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D1", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60c-src", "entity_2_idx": [[130, 139]], "entity_2_idx_in_text_with_entity_marker": [143, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1257_AIMed.d148.s1257.p2", "text": "Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro.", "text_with_entity_marker": "Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like [E1]cyclin A[/E1], was readily phosphorylated by [E2]pp60c-src[/E2] in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[90, 98]], "entity_1_idx_in_text_with_entity_marker": [94, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60c-src", "entity_2_idx": [[130, 139]], "entity_2_idx_in_text_with_entity_marker": [143, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1258_AIMed.d148.s1258.p0", "text": "In synchronized human osteosarcoma cells, cyclin D1 is induced in early G1 and becomes associated with p9Ckshs1, a Cdk-binding subunit.", "text_with_entity_marker": "In synchronized human osteosarcoma cells, [E1]cyclin D1[/E1] is induced in early G1 and becomes associated with [E2]p9Ckshs1[/E2], a Cdk-binding subunit.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D1", "entity_1_idx": [[42, 51]], "entity_1_idx_in_text_with_entity_marker": [46, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p9Ckshs1", "entity_2_idx": [[103, 111]], "entity_2_idx_in_text_with_entity_marker": [116, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1259_AIMed.d148.s1259.p0", "text": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "text_with_entity_marker": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that [E1]cyclin D1[/E1] is associated with both [E2]p34cdc2[/E2] and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D1", "entity_1_idx": [[106, 115]], "entity_1_idx_in_text_with_entity_marker": [110, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34cdc2", "entity_2_idx": [[140, 147]], "entity_2_idx_in_text_with_entity_marker": [153, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1259_AIMed.d148.s1259.p1", "text": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "text_with_entity_marker": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that [E1]cyclin D1[/E1] is associated with both p34cdc2 and [E2]p33cdk2[/E2], and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclin D1", "entity_1_idx": [[106, 115]], "entity_1_idx_in_text_with_entity_marker": [110, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p33cdk2", "entity_2_idx": [[152, 159]], "entity_2_idx_in_text_with_entity_marker": [165, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1259_AIMed.d148.s1259.p2", "text": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "text_with_entity_marker": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that [E1]cyclin D1[/E1] is associated with both p34cdc2 and p33cdk2, and that [E2]cyclin D1[/E2] immune complexes exhibit appreciable histone H1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D1", "entity_1_idx": [[106, 115]], "entity_1_idx_in_text_with_entity_marker": [110, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[170, 179]], "entity_2_idx_in_text_with_entity_marker": [183, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1259_AIMed.d148.s1259.p3", "text": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "text_with_entity_marker": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both [E1]p34cdc2[/E1] and [E2]p33cdk2[/E2], and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p34cdc2", "entity_1_idx": [[140, 147]], "entity_1_idx_in_text_with_entity_marker": [144, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p33cdk2", "entity_2_idx": [[152, 159]], "entity_2_idx_in_text_with_entity_marker": [165, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1259_AIMed.d148.s1259.p4", "text": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "text_with_entity_marker": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both [E1]p34cdc2[/E1] and p33cdk2, and that [E2]cyclin D1[/E2] immune complexes exhibit appreciable histone H1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p34cdc2", "entity_1_idx": [[140, 147]], "entity_1_idx_in_text_with_entity_marker": [144, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[170, 179]], "entity_2_idx_in_text_with_entity_marker": [183, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1259_AIMed.d148.s1259.p5", "text": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity.", "text_with_entity_marker": "Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and [E1]p33cdk2[/E1], and that [E2]cyclin D1[/E2] immune complexes exhibit appreciable histone H1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p33cdk2", "entity_1_idx": [[152, 159]], "entity_1_idx_in_text_with_entity_marker": [156, 163], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[170, 179]], "entity_2_idx_in_text_with_entity_marker": [183, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p0", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum [E1]retinol-binding protein[/E1] ([E2]RBP[/E2]) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinol-binding protein", "entity_1_idx": [[25, 48]], "entity_1_idx_in_text_with_entity_marker": [29, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[50, 53]], "entity_2_idx_in_text_with_entity_marker": [63, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p1", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to [E2]transthyretin[/E2] (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinol-binding protein", "entity_1_idx": [[25, 48]], "entity_1_idx_in_text_with_entity_marker": [29, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[58, 71]], "entity_2_idx_in_text_with_entity_marker": [71, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p2", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to transthyretin ([E2]TTR[/E2]) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinol-binding protein", "entity_1_idx": [[25, 48]], "entity_1_idx_in_text_with_entity_marker": [29, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p3", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to [E2]transthyretin[/E2] (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[58, 71]], "entity_2_idx_in_text_with_entity_marker": [71, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p4", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to transthyretin ([E2]TTR[/E2]) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p5", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum retinol-binding protein (RBP) to [E1]transthyretin[/E1] ([E2]TTR[/E2]) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transthyretin", "entity_1_idx": [[58, 71]], "entity_1_idx_in_text_with_entity_marker": [62, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p0", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum [E1]retinol-binding protein[/E1] ([E2]RBP[/E2]) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinol-binding protein", "entity_1_idx": [[64, 87]], "entity_1_idx_in_text_with_entity_marker": [68, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[89, 92]], "entity_2_idx_in_text_with_entity_marker": [102, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p1", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to [E2]transthyretin[/E2] (TTR) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinol-binding protein", "entity_1_idx": [[64, 87]], "entity_1_idx_in_text_with_entity_marker": [68, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[97, 110]], "entity_2_idx_in_text_with_entity_marker": [110, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p2", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to transthyretin ([E2]TTR[/E2]) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinol-binding protein", "entity_1_idx": [[64, 87]], "entity_1_idx_in_text_with_entity_marker": [68, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p3", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to [E2]transthyretin[/E2] (TTR) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[97, 110]], "entity_2_idx_in_text_with_entity_marker": [110, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p4", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to transthyretin ([E2]TTR[/E2]) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p5", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to [E1]transthyretin[/E1] ([E2]TTR[/E2]) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transthyretin", "entity_1_idx": [[97, 110]], "entity_1_idx_in_text_with_entity_marker": [101, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s19_AIMed.d2.s19.p0", "text": "DESIGN: We took advantage of previously collected data during a randomised double-blind, placebo-controlled clinical trial to conduct a secondary analysis of the RBP/TTR ratio and its relationship to infection and VA status.", "text_with_entity_marker": "DESIGN: We took advantage of previously collected data during a randomised double-blind, placebo-controlled clinical trial to conduct a secondary analysis of the [E1]RBP[/E1]/[E2]TTR[/E2] ratio and its relationship to infection and VA status.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[162, 165]], "entity_1_idx_in_text_with_entity_marker": [166, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[166, 169]], "entity_2_idx_in_text_with_entity_marker": [179, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s23_AIMed.d2.s23.p0", "text": "MAIN OUTCOME MEASURES: RBP/TTR molar ratio after 7 days hospitalisation.", "text_with_entity_marker": "MAIN OUTCOME MEASURES: [E1]RBP[/E1]/[E2]TTR[/E2] molar ratio after 7 days hospitalisation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[23, 26]], "entity_1_idx_in_text_with_entity_marker": [27, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[27, 30]], "entity_2_idx_in_text_with_entity_marker": [40, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p0", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:[E2]TTR[/E2] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p1", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E2]RBP[/E2]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p2", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E2]TTR[/E2] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[411, 414]], "entity_2_idx_in_text_with_entity_marker": [424, 427], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p3", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p4", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p5", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E2]RBP[/E2]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p6", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E2]TTR[/E2] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[411, 414]], "entity_2_idx_in_text_with_entity_marker": [424, 427], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p7", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p8", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p9", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E1]RBP[/E1]:[E2]TTR[/E2] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[411, 414]], "entity_2_idx_in_text_with_entity_marker": [424, 427], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p10", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E1]RBP[/E1]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p11", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E1]RBP[/E1]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p12", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E1]TTR[/E1] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[411, 414]], "entity_1_idx_in_text_with_entity_marker": [415, 418], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p13", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E1]TTR[/E1] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[411, 414]], "entity_1_idx_in_text_with_entity_marker": [415, 418], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p14", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E1]RBP[/E1]:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP", "entity_1_idx": [[604, 607]], "entity_1_idx_in_text_with_entity_marker": [608, 611], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d200.s1722_AIMed.d200.s1722.p0", "text": "Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.", "text_with_entity_marker": "Using epitope-tagging, interaction of [E1]E47[/E1] basic-helix-loop-helix protein with the [E2]eip1[/E2] protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E47", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "eip1", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d200.s1725_AIMed.d200.s1725.p0", "text": "Interactions with human PARP and mouse replication factor 1a were confirmed using glutathione transferase-tagged cDNAs.", "text_with_entity_marker": "Interactions with human [E1]PARP[/E1] and mouse [E2]replication factor 1a[/E2] were confirmed using glutathione transferase-tagged cDNAs.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PARP", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "replication factor 1a", "entity_2_idx": [[39, 60]], "entity_2_idx_in_text_with_entity_marker": [52, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d200.s1726_AIMed.d200.s1726.p0", "text": "A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.", "text_with_entity_marker": "A cDNA encoding part of the [E1]nucleolin[/E1] protein sequence interacted with the [E2]E47[/E2] basic-helix-loop-helix only when fused to a beta-galactosidase tag.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "nucleolin", "entity_1_idx": [[28, 37]], "entity_1_idx_in_text_with_entity_marker": [32, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E47", "entity_2_idx": [[75, 78]], "entity_2_idx_in_text_with_entity_marker": [88, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p0", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of [E1]K-ras[/E1], [E2]p53[/E2], p16 and DPC4/Smad4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[67, 72]], "entity_1_idx_in_text_with_entity_marker": [71, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[74, 77]], "entity_2_idx_in_text_with_entity_marker": [87, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p1", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of [E1]K-ras[/E1], p53, [E2]p16[/E2] and DPC4/Smad4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[67, 72]], "entity_1_idx_in_text_with_entity_marker": [71, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[79, 82]], "entity_2_idx_in_text_with_entity_marker": [92, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p2", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of [E1]K-ras[/E1], p53, p16 and [E2]DPC4[/E2]/Smad4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[67, 72]], "entity_1_idx_in_text_with_entity_marker": [71, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPC4", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p3", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of [E1]K-ras[/E1], p53, p16 and DPC4/[E2]Smad4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[67, 72]], "entity_1_idx_in_text_with_entity_marker": [71, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Smad4", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p4", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, [E1]p53[/E1], [E2]p16[/E2] and DPC4/Smad4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[79, 82]], "entity_2_idx_in_text_with_entity_marker": [92, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p5", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, [E1]p53[/E1], p16 and [E2]DPC4[/E2]/Smad4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPC4", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p6", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, [E1]p53[/E1], p16 and DPC4/[E2]Smad4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Smad4", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p7", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, [E1]p16[/E1] and [E2]DPC4[/E2]/Smad4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPC4", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p8", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, [E1]p16[/E1] and DPC4/[E2]Smad4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Smad4", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s60_AIMed.d8.s60.p9", "text": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.", "text_with_entity_marker": "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and [E1]DPC4[/E1]/[E2]Smad4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DPC4", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Smad4", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s61_AIMed.d8.s61.p0", "text": "The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "text_with_entity_marker": "The [E1]K-ras[/E1], [E2]p53[/E2], p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[11, 14]], "entity_2_idx_in_text_with_entity_marker": [24, 27], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s61_AIMed.d8.s61.p1", "text": "The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "text_with_entity_marker": "The [E1]K-ras[/E1], p53, [E2]p16[/E2] and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[16, 19]], "entity_2_idx_in_text_with_entity_marker": [29, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s61_AIMed.d8.s61.p2", "text": "The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "text_with_entity_marker": "The [E1]K-ras[/E1], p53, p16 and [E2]DPC4[/E2] genes are among those most frequently altered in pancreatic ductal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPC4", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s61_AIMed.d8.s61.p3", "text": "The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "text_with_entity_marker": "The K-ras, [E1]p53[/E1], [E2]p16[/E2] and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[11, 14]], "entity_1_idx_in_text_with_entity_marker": [15, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[16, 19]], "entity_2_idx_in_text_with_entity_marker": [29, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s61_AIMed.d8.s61.p4", "text": "The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "text_with_entity_marker": "The K-ras, [E1]p53[/E1], p16 and [E2]DPC4[/E2] genes are among those most frequently altered in pancreatic ductal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[11, 14]], "entity_1_idx_in_text_with_entity_marker": [15, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPC4", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s61_AIMed.d8.s61.p5", "text": "The K-ras, p53, p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma.", "text_with_entity_marker": "The K-ras, p53, [E1]p16[/E1] and [E2]DPC4[/E2] genes are among those most frequently altered in pancreatic ductal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPC4", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s63_AIMed.d8.s63.p0", "text": "These cell lines showed mutations in K-ras and p53 at frequencies of 91% and 95%, respectively.", "text_with_entity_marker": "These cell lines showed mutations in [E1]K-ras[/E1] and [E2]p53[/E2] at frequencies of 91% and 95%, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s66_AIMed.d8.s66.p0", "text": "The most typical mutational profile involved K-ras, p53, and p16INK4a, concurrently aberrated in 20 cases (91%).", "text_with_entity_marker": "The most typical mutational profile involved [E1]K-ras[/E1], [E2]p53[/E2], and p16INK4a, concurrently aberrated in 20 cases (91%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s66_AIMed.d8.s66.p1", "text": "The most typical mutational profile involved K-ras, p53, and p16INK4a, concurrently aberrated in 20 cases (91%).", "text_with_entity_marker": "The most typical mutational profile involved [E1]K-ras[/E1], p53, and [E2]p16INK4a[/E2], concurrently aberrated in 20 cases (91%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K-ras", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16INK4a", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d8.s66_AIMed.d8.s66.p2", "text": "The most typical mutational profile involved K-ras, p53, and p16INK4a, concurrently aberrated in 20 cases (91%).", "text_with_entity_marker": "The most typical mutational profile involved K-ras, [E1]p53[/E1], and [E2]p16INK4a[/E2], concurrently aberrated in 20 cases (91%).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16INK4a", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s109_AIMed.d13.s109.p0", "text": "We performed cell-free in vitro infection of primary bone marrow derived CD34+ cells using semi-purified HHV8 and a mature IL-2 dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1.", "text_with_entity_marker": "We performed cell-free in vitro infection of primary bone marrow derived [E1]CD34[/E1]+ cells using semi-purified HHV8 and a mature [E2]IL-2[/E2] dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD34", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[123, 127]], "entity_2_idx_in_text_with_entity_marker": [136, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s112_AIMed.d13.s112.p0", "text": "Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "text_with_entity_marker": "Of these 400, [E1]interferon regulatory factor 4[/E1] ([E2]IRF4[/E2]), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon regulatory factor 4", "entity_1_idx": [[14, 44]], "entity_1_idx_in_text_with_entity_marker": [18, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRF4", "entity_2_idx": [[46, 50]], "entity_2_idx_in_text_with_entity_marker": [59, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s112_AIMed.d13.s112.p1", "text": "Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "text_with_entity_marker": "Of these 400, [E1]interferon regulatory factor 4[/E1] (IRF4), [E2]cyclin B2[/E2], TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon regulatory factor 4", "entity_1_idx": [[14, 44]], "entity_1_idx_in_text_with_entity_marker": [18, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B2", "entity_2_idx": [[53, 62]], "entity_2_idx_in_text_with_entity_marker": [66, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s112_AIMed.d13.s112.p2", "text": "Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "text_with_entity_marker": "Of these 400, [E1]interferon regulatory factor 4[/E1] (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and [E2]pim 2[/E2] were up-regulated more than 3.5 fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon regulatory factor 4", "entity_1_idx": [[14, 44]], "entity_1_idx_in_text_with_entity_marker": [18, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pim 2", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s112_AIMed.d13.s112.p3", "text": "Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "text_with_entity_marker": "Of these 400, interferon regulatory factor 4 ([E1]IRF4[/E1]), [E2]cyclin B2[/E2], TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRF4", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B2", "entity_2_idx": [[53, 62]], "entity_2_idx_in_text_with_entity_marker": [66, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s112_AIMed.d13.s112.p4", "text": "Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "text_with_entity_marker": "Of these 400, interferon regulatory factor 4 ([E1]IRF4[/E1]), cyclin B2, TBP-associated factor, eukaryotic elongation factor and [E2]pim 2[/E2] were up-regulated more than 3.5 fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRF4", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pim 2", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d13.s112_AIMed.d13.s112.p5", "text": "Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.", "text_with_entity_marker": "Of these 400, interferon regulatory factor 4 (IRF4), [E1]cyclin B2[/E1], TBP-associated factor, eukaryotic elongation factor and [E2]pim 2[/E2] were up-regulated more than 3.5 fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin B2", "entity_1_idx": [[53, 62]], "entity_1_idx_in_text_with_entity_marker": [57, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pim 2", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1128_AIMed.d132.s1128.p0", "text": "Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.", "text_with_entity_marker": "Functional participation of the [E1-E2]IL-2[/E1] receptor gamma[/E2] chain in IL-7 receptor complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [39, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2[/E1] receptor gamma", "entity_2_idx": [[32, 51]], "entity_2_idx_in_text_with_entity_marker": [39, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1128_AIMed.d132.s1128.p1", "text": "Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.", "text_with_entity_marker": "Functional participation of the [E1]IL-2[/E1] receptor gamma chain in [E2]IL-7[/E2] receptor complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1128_AIMed.d132.s1128.p2", "text": "Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.", "text_with_entity_marker": "Functional participation of the [E1]IL-2[/E1] receptor gamma chain in [E2]IL-7 receptor[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7 receptor", "entity_2_idx": [[61, 74]], "entity_2_idx_in_text_with_entity_marker": [74, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1128_AIMed.d132.s1128.p3", "text": "Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.", "text_with_entity_marker": "Functional participation of the [E1]IL-2 receptor gamma[/E1] chain in [E2]IL-7[/E2] receptor complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2 receptor gamma", "entity_1_idx": [[32, 51]], "entity_1_idx_in_text_with_entity_marker": [36, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1128_AIMed.d132.s1128.p4", "text": "Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.", "text_with_entity_marker": "Functional participation of the [E1]IL-2 receptor gamma[/E1] chain in [E2]IL-7 receptor[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2 receptor gamma", "entity_1_idx": [[32, 51]], "entity_1_idx_in_text_with_entity_marker": [36, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7 receptor", "entity_2_idx": [[61, 74]], "entity_2_idx_in_text_with_entity_marker": [74, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1128_AIMed.d132.s1128.p5", "text": "Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.", "text_with_entity_marker": "Functional participation of the IL-2 receptor gamma chain in [E1-E2]IL-7[/E1] receptor[/E2] complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7[/E1] receptor", "entity_2_idx": [[61, 74]], "entity_2_idx_in_text_with_entity_marker": [68, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p0", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1]interleukin-2[/E1] ([E2]IL-2[/E2]) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [27, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [51, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p1", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1-E2]interleukin-2[/E1] (IL-2) receptor[/E2] is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [30, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-2[/E1] (IL-2) receptor", "entity_2_idx": [[23, 52]], "entity_2_idx_in_text_with_entity_marker": [30, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p2", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1]interleukin-2[/E1] (IL-2) receptor is shared with the functional [E2]IL-4[/E2] receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [27, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p3", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1]interleukin-2[/E1] (IL-2) receptor is shared with the functional [E2]IL-4 receptor[/E2] and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [27, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4 receptor", "entity_2_idx": [[83, 96]], "entity_2_idx_in_text_with_entity_marker": [96, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p4", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1]interleukin-2 (IL-2) receptor[/E1][E2]IL-2[/E2]) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2 (IL-2) receptor", "entity_1_idx": [[23, 52]], "entity_1_idx_in_text_with_entity_marker": [27, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p5", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the interleukin-2 ([E1]IL-2[/E1]) receptor is shared with the functional [E2]IL-4[/E2] receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p6", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the interleukin-2 ([E1]IL-2[/E1]) receptor is shared with the functional [E2]IL-4 receptor[/E2] and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4 receptor", "entity_2_idx": [[83, 96]], "entity_2_idx_in_text_with_entity_marker": [96, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p7", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1]interleukin-2 (IL-2) receptor[/E1] is shared with the functional [E2]IL-4[/E2] receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2 (IL-2) receptor", "entity_1_idx": [[23, 52]], "entity_1_idx_in_text_with_entity_marker": [27, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p8", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the [E1]interleukin-2 (IL-2) receptor[/E1] is shared with the functional [E2]IL-4 receptor[/E2] and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-2 (IL-2) receptor", "entity_1_idx": [[23, 52]], "entity_1_idx_in_text_with_entity_marker": [27, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4 receptor", "entity_2_idx": [[83, 96]], "entity_2_idx_in_text_with_entity_marker": [96, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1129_AIMed.d132.s1129.p9", "text": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "text_with_entity_marker": "The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional [E1-E2]IL-4[/E1] receptor[/E2] and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[83, 87]], "entity_1_idx_in_text_with_entity_marker": [90, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4[/E1] receptor", "entity_2_idx": [[83, 96]], "entity_2_idx_in_text_with_entity_marker": [90, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d132.s1130_AIMed.d132.s1130.p0", "text": "Studies with monoclonal antibodies specific for the IL-2 receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for IL-7 that are involved in the differentiation of T and B cells.", "text_with_entity_marker": "Studies with monoclonal antibodies specific for the [E1]IL-2[/E1] receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for [E2]IL-7[/E2] that are involved in the differentiation of T and B cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
